China Jo-Jo Drugstores 10-Q 12 Nov 15 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Sep. 30, 2015	Nov. 11, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	CHINA JO-JO DRUGSTORES, INC.
Entity Central Index Key	1,413,263
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		16,850,504

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2015	Mar. 31, 2015
CURRENT ASSETS
Cash	$ 6,709,585	$ 4,023,581
Financial assets available for sale		1,307,200
Restricted cash	$ 12,811,003	8,992,101
Notes receivable	37,728	138,952
Trade accounts receivable, net	8,514,466	9,237,743
Inventories	11,393,972	10,538,591
Other receivables, net	1,863,967	1,130,264
Advances to suppliers, net	4,740,561	4,717,352
Other current assets	1,529,125	2,200,838
Total current assets	47,600,407	42,286,622
PROPERTY AND EQUIPMENT, net	6,165,063	$ 7,056,781
OTHER ASSETS
Long-term investment	110,040
Farmland assets	1,717,454	$ 1,704,359
Long term deposits	2,485,977	2,584,025
Other noncurrent assets	2,631,030	2,734,798
Intangible assets, net	3,006,646	3,142,003
Total other assets	9,951,147	10,165,185
Total assets	63,716,617	59,508,588
CURRENT LIABILITIES
Short-term loan payable	23,580	32,680
Accounts payable, trade	18,154,740	15,915,915
Notes payable	16,923,068	15,752,969
Other payables	3,862,452	2,931,869
Other payables - related parties	$ 2,759,574	$ 2,729,740
Loan from third parties
Customer deposits	$ 1,224,334	$ 3,759,050
Taxes payable	429,331	328,111
Accrued liabilities	553,151	509,537
Total current liabilities	43,930,230	41,959,871
Purchase option and warrant liability	157,261	315,327
Total liabilities	$ 44,087,491	$ 42,275,198
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Preferred stock; $0.001 par value; 10,000,000 shares authorized; nil issued and outstanding as of September 30, 2015 and March 31, 2015
Common stock; $0.001 par value; 250,000,000 shares authorized; 16,850,504 and 15,650,504 shares issued and outstanding as of September 30, 2015 and March 31, 2015	$ 16,851	$ 15,651
Additional paid-in capital	22,247,600	19,301,233
Statutory reserves	1,309,109	1,309,109
Accumulated deficit	(7,142,424)	(7,404,210)
Accumulated other comprehensive income	3,197,990	3,972,543
Total stockholders' equity	$ 19,629,126	17,194,326
Noncontrolling interests		39,064
Total equity	$ 19,629,126	17,233,390
Total liabilities and stockholders' equity	$ 63,716,617	$ 59,508,588

Consolidated Balance Sheets (U3

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2015	Mar. 31, 2015
Statement Of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	16,850,504	15,650,504
Common stock, shares outstanding	16,850,504	15,650,504

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
REVENUES, NET	$ 22,577,626	$ 18,444,065	$ 43,888,918	$ 34,903,297
COST OF GOODS SOLD	18,600,619	15,678,808	35,536,228	29,627,421
GROSS PROFIT	3,977,007	2,765,257	8,352,690	5,275,876
SELLING EXPENSES	3,418,755	1,933,780	6,515,124	3,702,357
GENERAL AND ADMINISTRATIVE EXPENSES	839,842	746,175	1,760,072	1,827,376
TOTAL OPERATING EXPENSES	4,258,597	2,679,955	8,275,196	5,529,733
(LOSS) INCOME FROM OPERATIONS	(281,590)	85,302	77,494	(253,857)
OTHER (LOSS) INCOME, NET	193,800	(52,692)	70,351	(168,528)
CHANGE IN FAIR VALUE OF DERIVATIVE LIABILITIES	200,903	(47,342)	158,066	76,357
INCOME (LOSS) BEFORE INCOME TAXES	113,113	(14,732)	305,911	(346,028)
PROVISION FOR INCOME TAXES	(38,062)	22,680	44,125	38,821
NET INCOME (LOSS)	$ 151,175	(37,412)	$ 261,786	(384,849)
NET (LOSS) ATTRIBUTABLE TO NONCONTROLLING INTEREST		(1,219)		(1,919)
NET INCOME (LOSS) ATTRIBUTABLE TO CHINA JO-JO DRUGSTORES, INC.	$ 151,175	(36,193)	$ 261,786	(382,930)
OTHER COMPREHENSIVE (LOSS) INCOME
Foreign currency translation adjustments	(860,853)	6,192	(774,553)	58,460
COMPREHENSIVE (LOSS)	$ (709,678)	$ (30,001)	$ (512,767)	$ (324,470)
WEIGHTED AVERAGE NUMBER OF SHARES:
Basic	16,537,461	14,981,637	16,096,406	14,700,375
Diluted	16,588,559	14,981,637	16,147,505	14,700,375
LOSS PER SHARES:
Basic	$ 0.01	$ 0	$ 0.02	$ (0.03)
Diluted	$ 0.01	$ 0	$ 0.02	$ (0.03)

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 261,786	$ (384,849)
Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities:
Depreciation and amortization	763,839	832,570
Stock-based compensation	208,450	129,692
Bad debt provision	$ (1,540,695)	(1,611,497)
Inventory reserve		136,575
Change in fair value of purchase option derivative liability	$ (158,066)	(76,357)
Change in operating assets:
Accounts receivable, trade	716,075	694,722
Notes receivable	98,698	(64,932)
Inventories	(1,371,177)	(1,501,054)
Other receivables	(556,942)	(425,699)
Advances to suppliers	748,185	3,207,686
Other current assets	$ 615,329	192,254
Long term deposit		337,326
Other noncurrent assets		186,680
Change in operating liabilities:
Accounts payable, trade	$ 2,924,110	(557,095)
Other payables and accrued liabilities	1,133,850	252,409
Customer deposits	(2,460,559)	409,600
Taxes payable	116,924	43,762
Net cash provided by operating activities	1,499,807	1,801,793
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment	(106,200)	$ (246,097)
Decrease in Financial assets available for sale	1,293,600
Investment in a joint venture	$ (113,190)
Additions to leasehold improvements		$ (12,485)
Net cash provided by (used in) investing activities	$ 1,074,210	(258,582)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from short-term bank loan	23,580	32,466
Repayment of short-term bank loan	$ (31,665)	(162,330)
Repayment of third parties loan		(59,529)
Change in restricted cash	$ (4,279,182)	(2,364,687)
Repayments of notes payable	(15,589,077)	(7,822,163)
Proceeds from notes payable	17,407,506	11,193,465
Proceeds from other payables-related parties	69,977	$ 463,848
Proceeds from equity financing	2,699,500
Net cash provided by financing activities	300,639	$ 1,281,070
EFFECT OF EXCHANGE RATE ON CASH	(188,652)	83,166
INCREASE IN CASH	2,686,004	2,907,447
CASH, beginning of period	4,023,581	4,445,276
CASH, end of period	6,709,585	7,352,723
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest	158,415	1,458
Cash paid for income taxes	$ 35,943	43,788
Issuance of common stocks in exchange of debts		941,613
Reclassification of leasehold improvement to equipment		$ 37,011
Non-cash financing activities:
Issuance of stock purchase options to an investor	$ 1,231,067
Issuance of stock purchase options to an investment bank	$ 147,728

Description of Business and Org

Description of Business and Organization	6 Months Ended
	Sep. 30, 2015
Description of Business and Organization [Abstract]
DESCRIPTION OF BUSINESS AND ORGANIZATION	Note 1 – DESCRIPTION OF BUSINESS AND ORGANIZATION China Jo-Jo Drugstores, Inc. (“Jo-Jo Drugstores” or the “Company”), was incorporated in Nevada on December 19, 2006, originally under the name “Kerrisdale Mining Corporation.” On September 24, 2009, the Company changed its name to “China Jo-Jo Drugstores, Inc.” in connection with a share exchange transaction as described below. On September 17, 2009, the Company completed a share exchange transaction with Renovation Investment (Hong Kong) Co., Ltd. (“Renovation”), whereby 7,900,000 shares of common stock were issued to the stockholders of Renovation in exchange for 100% of the capital stock of Renovation. The completion of the share exchange transaction resulted in a change of control. The share exchange transaction was accounted for as a reverse acquisition and recapitalization and, as a result, the consolidated financial statements of the Company (the legal acquirer) are, in substance, those of Renovation (the accounting acquirer), with the assets and liabilities, and revenues and expenses, of the Company being included effective from the date of the share exchange transaction. Renovation has no substantive operations of its own except for its holdings of Zhejiang Jiuxin Investment Management Co., Ltd. (“Jiuxin Management”), Zhejiang Shouantang Medical Technology Co., Ltd. (“Shouantang Technology”) and Hangzhou Jiutong Medical Technology Co., Ltd (“Jiutong Medical”), its wholly-owned subsidiaries. The Company is a retail, both online and offline, and wholesale distributor of pharmaceutical and other healthcare products in the People’s Republic of China (“China” or the “PRC”). The Company’s offline retail business is comprised primarily of pharmacies, a majority of which are operated by Hangzhou Jiuzhou Grand Pharmacy Chain Co., Ltd. (“Jiuzhou Pharmacy”), a company that the Company controls through contractual arrangements. The Company’s offline retail business also includes four medical clinics through Hangzhou Jiuzhou Clinic of Integrated Traditional and Western Medicine (“Jiuzhou Clinic”) and Hangzhou Jiuzhou Medical and Public Health Service Co., Ltd. (“Jiuzhou Service”), both of which are also controlled by the Company through contractual arrangements. On December 18, 2013, Jiuzhou Service established, and held 51% of, Hangzhou Shouantang Health Management Co., Ltd. (“Shouantang Health”), a PRC company licensed to sell health care products. Shouantang Health was closed in April 2015. The Company’s online pharmacy license remains with Jiuzhou Pharmacy and its online retail pharmacy business are primarily conducted through Zhejiang Quannuo Internet Technology Co., Ltd. (“Quannuo Technology”), which provides technical, sales and logistic support. In May 2015, the Company established Zhejiang Jianshun Network Technology Co. Ltd, a joint venture with Shanghai Jianbao Technology Co., Ltd., in order to develop its online pharmaceutical sales from large commercial medical insurance companies. On September 10, 2015, Renovation set up a new entity named Hangzhou JiuYi Medical Technology Co. Ltd,(“Jiuyi” to provide additional technical support such as webpage development to our online pharmacy business. The Company’s wholesale business is primarily conducted through Zhejiang Jiuxin Medicine Co., Ltd. (“Jiuxin Medicine”), which is licensed to distribute prescription and non-prescription pharmaceutical products throughout China. Jiuzhou Pharmacy acquired Jiuxin Medicine on August 25, 2011. The Company’s herb farming business is conducted by Hangzhou Qianhong Agriculture Development Co., Ltd. (“Qianhong Agriculture”), a wholly-owned subsidiary of Jiuxin Management, which operates a cultivation project of herbal plants used for traditional Chinese medicine (“TCM”). The accompanying consolidated financial statements reflect the activities of the Company and each of the following entities: Entity Name Background Ownership Renovation HK ● Incorporated in Hong Kong SAR on September 2, 2008 100% Jiuxin Management ● Established in the PRC on October 14, 2008 ● Deemed a wholly foreign owned enterprise (“WFOE”) under PRC law ● Registered capital of $4.5 million fully paid 100% Shouantang Technology ● Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million ● Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid ● Deemed a WFOE under PRC law ● Invests and finances the working capital of Quannuo Technology 100% Qianhong Agriculture ● Established in the PRC on August 10, 2010 by Jiuxin Management ● Registered capital of RMB 10 million fully paid ● Carries out herb farming business 100% Quannuo Technology ● Established in the PRC on July 7, 2009 ● Registered capital of RMB 10 million fully paid ● Acquired by Shouantang Technology in November 2010 ● Operates the Company’s online pharmacy website and provide software and technical support 100% Hangzhou Quannuo ● Established in the PRC on July 8, 2010 by Quannuo Technology ● Registered capital of RMB 800,000 fully paid ● Currently has no operation and has closed, pending dissolution 100% Jiuzhou Pharmacy (1) ● Established in the PRC on September 9, 2003 ● Registered capital of RMB 5 million fully paid ● Operates the “Jiuzhou Grand Pharmacy” stores in Hangzhou VIE by contractual arrangements (2) Jiuzhou Clinic (1) ● Established in the PRC as a general partnership on October 10, 2003 ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores VIE by contractual arrangements (2) Jiuzhou Service (1) ● Established in the PRC on November 2, 2005 ● Registered capital of RMB 500,000 fully paid ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores VIE by contractual arrangements (2) Jiuxin Medicine ● Established in PRC on December 31, 2003 ● Acquired by Jiuzhou Pharmacy in August 2011 ● Registered capital of RMB 10 million fully paid ● Carries out pharmaceutical distribution services VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiutong Medical ● Established in the PRC on December 20, 2011 by Renovation ● Registered capital of $2.6 million fully paid ● Currently has no operation 100% Shouantang Bio ● Established in the PRC in October, 2014 by Shouantang Technology ● 100% held by Shouantang Technology ● Registered capital of RMB 1,000,000 fully paid ● Sells nutritional supplements under its own brand name VIE by contractual arrangements as a controlled entity of Jiuzhou Service (2) Jianshun ● Established in the PRC in May, 2015 ● 35% held by Jiuzhou Pharmacy ● Manages sales on official website of the online pharmacy VIE by contractual arrangements as a controlled entity of Jiuzhou Pharmacy (2) Jiuyi Technology ● Established in the PRC on September 10, 2015 ● 100% held by Renovation HK ● Technical support to online pharmacy 100% (1) Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service have been under the common control of the three shareholders of Renovation (the “Owners”) since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. Operationally, the Owners have operated these three companies in conjunction with one another since each company’s respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy, as is Shouantang Health as a subsidiary of Jiuzhou Service and Jianshun as a subsidiary of Jiuzhou Pharmacy. (2) To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. As a result of these agreements, which obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for all three companies (as well as one subsidiary of Jiuzhou Pharmacy) as a variable interest entity (“VIE”) under the accounting standards of the Financial Accounting Standards Board (“FASB”). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiary under the control of Jiuzhou Pharmacy (Shouantang Health), are consolidated into the financial statements of the Company.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Sep. 30, 2015
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Note 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation and consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles (“US GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. These condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2015 filed with the SEC on June 29, 2015. Operating results for the three and six months ended September 30, 2015 may not be necessarily indicative of the results that may be expected for the full year. The condensed consolidated financial statements include the financial statements of the Company, its subsidiaries and VIEs. All significant inter-company transactions and balances between the Company, its subsidiaries and VIEs are eliminated upon consolidation. Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no effect on net income or cash flows as previously reported. Consolidation of variable interest entities In accordance with accounting standards regarding consolidation of variable interest entities, VIEs are generally entities that lack sufficient equity to finance their activities without additional financial support from other parties or whose equity holders lack adequate decision making ability. All VIEs with which the Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary is required to consolidate the VIE for financial reporting purposes. The Company has concluded, based on the contractual arrangements, that Jiuzhou Pharmacy (including its subsidiaries and controlled entities), Jiuzhou Clinic and Jiuzhou Service are each a VIE and that the Company’s wholly-owned subsidiary, Jiuxin Management, absorbs a majority of the risk of loss from the activities of these companies, thereby enabling the Company, through Jiuxin Management, to receive a majority of their respective expected residual returns. Additionally, as Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service are under common control, the consolidated financial statements have been prepared as if the transactions had occurred retroactively as to the beginning of the reporting period of these consolidated financial statements. Control and common control are defined under the accounting standards as “an individual, enterprise, or immediate family members who hold more than 50 percent of the voting ownership interest of each entity.” Because the Owners collectively own 100% of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and have agreed to vote their interests in concert since the establishment of each of these three companies as memorialized the Voting Rights Proxy Agreement, the Company believes that the Owners collectively have control and common control of the three companies. Accordingly, the Company believes that Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service were constructively held under common control by Jiuxin Management as of the time the Contractual Agreements were entered into, establishing Jiuxin Management as their primary beneficiary. Jiuxin Management, in turn, is owned by Renovation, which is owned by the Company. Risks and Uncertainties The operations of the Company are located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company’s operations in the PRC are subject to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company’s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results. The Company has significant cash deposits with suppliers in order to obtain and maintain inventory. The Company’s ability to obtain products and maintain inventory at existing and new locations is dependent upon its ability to post and maintain significant cash deposits with its suppliers. In the PRC, many vendors are unwilling to extend credit terms for product sales that require cash deposits to be made. The Company does not generally receive interest on any of its supplier deposits, and such deposits are subject to loss as a result of the creditworthiness or bankruptcy of the party who holds such funds, as well as the risk from illegal acts such as conversion, fraud, theft or dishonesty associated with the third party. If these circumstances were to arise, the Company would find it difficult or impossible, due to the unpredictability of legal proceedings in China, to recover all or a portion of the amount on deposit with its vendors or landlords. Members of the current management team own controlling interests in the Company and are also the Owners of the VIEs in the PRC. The Company only controls the VIEs through contractual arrangements which obligate it to absorb the risk of loss and to receive the residual expected returns. As such, the controlling shareholders of the Company and the VIEs could cancel these agreements or permit them to expire at the end of the agreement terms, as a result of which the Company would not retain control of the VIEs. Use of estimates The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The significant estimates made in the preparation of the accompanying unaudited condensed consolidated financial statements relate to the assessment of the carrying values of accounts receivable, advances to suppliers and related allowance for doubtful accounts, useful lives of property and equipment, inventory reserve and fair value of its purchase option derivative liability. Because of the use of estimates inherent in the financial reporting process, actual results could materially differ from those estimates. Fair value measurements The Company has adopted ASC Topic 820, Fair Value Measurement and Disclosure, which defines fair value, establishes a framework for measuring fair value in GAAP, and expands disclosures about fair value measurements. It does not require any new fair value measurements, but provides guidance on how to measure fair value by providing a fair value hierarchy used to classify the source of the information. It establishes a three-level valuation hierarchy of valuation techniques based on observable and unobservable inputs, which may be used to measure fair value and include the following: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Classification within the hierarchy is determined based on the lowest level of input that is significant to the fair value measurement. The Company's financial assets and liabilities, which include financial instruments as defined by ASC 820, include cash and cash equivalents, accounts receivable, accounts payable, long-term debt and derivatives. The carrying amounts of cash and cash equivalents, financial assets available for sales, accounts receivable, notes receivables, and accounts payable are a reasonable approximation of fair value due to the short maturities of these instruments (Level 1). The carrying amount of notes payable approximates fair value based on borrowing rates of similar bank loan currently available to the Company (Level 2) (See Note 12). The carrying amount of the Company's warrants is recorded at fair value and is determined based on observable inputs that are corroborated by market data (Level 2). As of September 30, 2015 and March 31, 2015, the fair values of our derivative instruments that were carried at fair value. (See Note 16) Revenue recognition Revenue from sales of prescription medicine at the drugstores is recognized when the prescription is filled and the customer picks up and pays for the prescription. Revenue from sales of other merchandise at the drugstores is recognized at the point of sale, which is when a customer pays for and receives the merchandise. Usually the majority of our merchandise such as prescription and OTC drugs are not allowed to be returned after the customers leave the counter. Return of other products such as sundry products are minimal. Sales of drugs reimbursed by the local government medical insurance agency and receivables from the agency are recognized when a customer pays for the drugs at a store. Based on historical experience, a reserve for potential loss from denial of reimbursement on certain unqualified drugs is made to the receivables from the government agency. Revenue from medical services is recognized after the service has been rendered to a customer. Revenue from online pharmacy sales is recognized when merchandise is shipped to customers. While most deliveries take one day, certain deliveries may take longer depending on a customer’s location. Any loss caused in a shipment will be reimbursed by the Company’s courier company. Our sales policy allows return of certain merchandises without reasons within seven days after customer’s receipts of merchandise. A proper sales reserve is made to account for the potential loss from returns from customers. Historically, sales returns seven days after merchandise receipts have been minimal. Revenue from sales of merchandise to non-retail customers is recognized when the following conditions are met: (1) persuasive evidence of an arrangement exists (sales agreements and customer purchase orders are used to determine the existence of an arrangement); (2) delivery of goods has occurred and risks and benefits of ownership have been transferred, which is when the goods are received by the customer at its designated location in accordance with the sales terms; (3) the sales price is fixed or determinable; and (4) collectability is probable. Historically, sales returns have been minimal. The Company’s revenue is net of value added tax (“VAT”) collected on behalf of PRC tax authorities in respect to the sales of merchandise. VAT collected from customers, net of VAT paid for purchases, is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant PRC tax authorities. Restricted cash The Company’s restricted cash consists of cash in a bank as security for its notes payable. The Company has notes payable outstanding with the bank and is required to keep certain amounts on deposit that are subject to withdrawal restrictions. The notes payable are generally short term in nature due to their short maturity period of six to nine months; thus, restricted cash is classified as a current asset. Accounts receivable Accounts receivable represents the following: (1) amounts due from banks relating to retail sales that are paid or settled by the customers’ debit or credit cards, (2) amounts due from government social security bureaus and commercial health insurance programs relating to retail sales of drugs, prescription medicine, and medical services that are paid or settled by the customers’ medical insurance cards, (3) amounts due from non-bank third party payment instruments such as Alipay from certain e-commerce platforms and (4) amounts due from non-retail customers for sales of merchandise. Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts, as necessary. In the Company’s retail business, accounts receivable mainly consist of reimbursements due from the government insurance bureaus and commercial health insurance programs and are usually collected within two or three months. The Company directly writes off delinquent account balances, which is determined to be uncollectible after confirming with the appropriate bureau or program each month. Additionally, the Company also makes estimated reserves on related outstanding accounts receivable based on historical trend. In the Company’s online pharmacy business, accounts receivables primarily consist of amounts due from non-bank third party payment instruments such as Alipay from certain e-commerce platforms. To purchase pharmaceutical products from the e-commerce platforms such as Tmall, customers are required to pay to certain non-bank third party payment instruments such as Alipay, which, in turn, will reimburse the Company within seven days to a month. Except for customer returns of sold products, the receivables from these payments instruments are rarely uncollectible. In its wholesale business, the Company uses the aging method to estimate the allowance for anticipated uncollectible receivable balances. Under the aging method, bad debt percentages are determined by management, based on historical experience and the current economic climate, are applied to customers’ balances categorized by the number of months the underlying invoices have remained outstanding. At each reporting period, the allowance balance is adjusted to reflect the amount computed as a result of the aging method. When facts subsequently become available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account as a change in estimate. Inventories Inventories are stated at the lower of cost or market value. Cost is determined by the first in first out (FIFO) method. Market value is the lower of replacement cost or net realizable value. The Company carries out physical inventory counts on a monthly basis at each store and warehouse. The Company periodically reviews its inventory and records write-downs to inventories for shrinkage losses and damaged merchandise that are identified. The Company provides a reserve for estimated inventory obsolescence or excess quantities on hand equal to the difference , if any, between the cost of the inventory and its estimated realizable value. Farmland assets Herbs that the Company farms are recorded at their costs, which includes direct costs such as seed selection, fertilizer, and labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development costs. Since April 2014, amortization of farmland development costs has been expensed instead of allocated into inventory due to unpredictable future market value of planted gingko trees. All related costs described in the above are accumulated until the time of harvest and then allocated to harvested herbs when they are sold. Property and equipment Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is calculated on the straight-line method over the estimated useful lives of the assets, taking into consideration the assets’ estimated residual value. Leasehold improvements are amortized over the shorter of lease term or remaining lease period of the underlying assets. Following are the estimated useful lives of the Company’s property and equipment: Estimated Useful Life Leasehold improvements 3-10 years Motor vehicles 3-5 years Office equipment & furniture 3-5 years Buildings 35 years Maintenance, repairs and minor renewals are charged to expenses as incurred. Major additions and betterment to property and equipment are capitalized. Intangibles Intangible assets are acquired individually or as part of a group of assets, and are initially recorded at their fair value. The cost of a group of assets acquired in a transaction is allocated to the individual assets based on their relative fair values. The estimated useful lives of the Company’s intangible assets are as follows: Estimated Useful Life Land use right 50 years Software 3 years The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate that the assets might be impaired. Impairment of long lived assets The Company evaluates long lived tangible and intangible assets for impairment, whenever events or changes in circumstances indicate that the carrying value may not be recoverable from its estimated future cash flows. Recoverability is measured by comparing the assets’ net book value to the related projected undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections, market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset is considered impaired, and a second test is performed to measure the amount of impairment loss. There was no additional impairment occurred during fiscal 2015. Notes payable During the normal course of business, the Company regularly issues bank acceptance bills as a payment method to settle outstanding accounts payables with various material suppliers. The Company records such bank acceptance bills as notes payable. Such notes payable are generally short term in nature due to their short maturity period of six to nine months. Income taxes The Company records income taxes pursuant to the accounting standards for income taxes. These standards require the recognition of deferred income tax liabilities and assets for the expected future tax consequences of temporary differences between income tax basis and financial reporting basis of assets and liabilities. Provision for income taxes consists of taxes currently due and the net change in deferred taxes. A valuation allowance is recognized if it is more likely than not that some portion, or all of, a deferred tax asset will not be realized. The accounting standards clarify the accounting and disclosure requirements for uncertain tax positions and prescribe a recognition threshold and measurement attribute for recognition and measurement of a tax position taken or expected to be taken in a tax return. The accounting standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. No significant penalties, uncertain tax provisions or interest relating to income taxes were incurred during the periods ended September 30, 2015 and 2014. Value added tax Sales revenue represents the invoiced value of goods, net of VAT. All of the Company’s products are sold in the PRC and are subjected to a VAT on the gross sales price. The VAT rates range up to 17%, depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing or acquiring its finished products. The Company recorded a VAT payable net of payments in the accompanying financial statements. Stock based compensation The Company follows the provisions of ASC 718, “Compensation — Stock Compensation,” which establishes accounting standards for non-employee and employee stock-based awards. Under the provisions of ASC 718, the fair value of stock issued is used to measure the fair value of services received as the Company believes such approach is a more reliable method of measuring the fair value of the services. For non-employee stock-based awards, fair value is measured based on the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is calculated and then recognized as compensation expense over the requisite performance period. For employee stock-based awards, share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense with graded vesting on a straight–line basis over the requisite service period for the entire award. Advertising and promotion costs Advertising and promotion costs are expensed as incurred and amounted to $134,887 and $81,321 for three months ended September 30, 2015 and 2014, respectively, and $198,053 and $131,239 for the six months ended September 30, 2015 and 2014, respectively. Such costs consist primarily of print and promotional materials such as flyers to local communities. Operating leases The Company leases premises for retail drugstores, offices and wholesale warehouse under non-cancelable operating leases. Operating lease payments are expensed over the term of lease. A majority of the Company’s retail drugstore leases have a 3 to 8 year term with a renewal option upon the expiration of the lease; the wholesale warehouse lease has a 10-year term with a renewal option upon the expiration of the lease. The Company has historically been able to renew a majority of its drugstores leases. Under the terms of the lease agreements, the Company has no legal or contractual asset retirement obligations at the end of the lease. In addition, land leased from the government is amortized on a straight-line basis over a 30-year term. Foreign currency translation The Company uses the United States dollar (“U.S. dollars” or “USD”) for financial reporting purposes. The Company’s subsidiaries and VIEs maintain their books and records in their functional currency the Renminbi (“RMB”), the currency of the PRC. In general, for consolidation purposes, the Company translates the assets and liabilities of its subsidiaries and VIEs into U.S. dollars using the applicable exchange rates prevailing at the balance sheet date, and the statements of income and cash flows are translated at average exchange rates during the reporting period. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the financial statements of the subsidiaries and VIEs are recorded as accumulated other comprehensive income. The balance sheet amounts, with the exception of equity, at September 30, 2015 and March 31, 2015 were translated at 1 RMB to $0.1572 USD and at 1 RMB to $0.1634 USD, respectively. The average translation rates applied to income and cash flow statement amounts for the six months ended September 30, 2015 and 2014 were at 1 RMB to $0.1617 USD and at 1 RMB to $0.1623 USD, respectively. Concentrations and credit risk Certain financial instruments, which subject the Company to concentration of credit risk, consist of cash and restricted cash. The Company has cash balances at financial institutions located in Hong Kong and PRC. Balances at financial institutions in Hong Kong may, from time to time, exceed Hong Kong Deposit Protection Board’s insured limits. Since March 31, 2015, balances at financial institutions and state-owned banks within the PRC are covered by insurance up to (USDRMB 500,000 per bank. As of September 30, 2015 and March 31, 2015, the Company had deposits totaling $16,404,370 and $12,563,579 that were covered by such an insurance in China, respectively. To date, the Company has not experienced any losses in such accounts. For the three months ended September 30, 2015, the two largest vendors accounted for 24.5% of the Company’s total purchases and one vendor accounted for 18.2% of total advances to suppliers. For the three months ended September 30, 2014, the two largest vendors accounted for 24.5% of the Company’s total purchases and one vendor accounted for 18.2% of total advances to suppliers. For the six months ended September 30, 2015, the two largest vendors accounted for 25.3% of the Company’s total purchases and one vendor accounted for 18.2% of total advances to suppliers. For the six months ended September 30, 2014, the two largest vendors accounted for 25.3% of the Company’s total purchases and one vendor accounted for 18.2% of total advances to suppliers. For the three months ended September 30, 2015, no customer accounted for more than 10% of the Company’s total sales or accounts receivable. For the three months ended September 30, 2014, no customer accounted for more than 10% of the Company’s total sales or accounts receivable. For the six months ended September 30, 2015, no customer accounted for more than 10% of the Company’s total sales or accounts receivable. For the six months ended September 30, 2014, no customer accounted for more than 10% of the Company’s total sales or accounts receivable. Recent Accounting Pronouncements In June 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-10, “Technical Corrections and Improvements” (“ASU 2015-10”). The amendments in ASU 2015-10 cover a wide range of Topics in the Accounting Standards Codification (the “ASC”). The amendments in ASU 2015-10 represent changes to clarify the ASC, correct unintended application of guidance, or make minor improvements to the ASC that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. Additionally, some of the amendments will make the ASC easier to understand and easier to apply by eliminating inconsistencies, providing needed clarifications, and improving the presentation of guidance in the ASC. Transition guidance varies based on the amendments in ASU 2015-10. The amendments in ASU 2015-10 that require transition guidance are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. All other amendments will be effective upon the issuance of ASU 2015-10. We are currently in the process of evaluating the impact of the adoption of ASU 2015-02 on our consolidated financial statements. In July 2015, the FASB issued ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory” (“ASU 2015-11”). The amendments in this update require an entity to measure inventory within the scope of ASU 2015-11 (the amendments in ASU 2015-11 do not apply to inventory that is measured using last-in, first-out or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out or average cost) at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is uncharged for inventory measured using last-in, first-out or the retail inventory method. The amendments in ASU 2015-11 more closely align the measurement of inventory in U.S. GAAP with the measurement of inventory in International Financial Reporting Standards (“IFRS”). ASU 2015-11 is effective for public business entities for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The amendments in ASU 2015-11 should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. We are currently in the process of evaluating the impact of the adoption of ASU 2015-02 on our consolidated financial statements. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which defers the effective date of ASU 2014-09 for all entities by one year. Public business entities, certain not-for-profit entities, and certain employee benefit plans should apply the guidance in ASU 2014-09 to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Currently, the Company is evaluating the impact of our pending adoption of ASU 2014-09 and ASU 2015-14 on its consolidated financial statements and has not yet determined the method by which it will adopt the standard in year 2018.

Trade Accounts Receivable

Trade Accounts Receivable	6 Months Ended
	Sep. 30, 2015
Trade Accounts Receivable [Abstract]
TRADE ACCOUNTS RECEIVABLE	NOTE 3 – TRADE ACCOUNTS RECEIVABLE Trade accounts receivable consisted of the following: September 30, March 31, Accounts receivable $ 10,618,786 $ 12,108,561 Less: allowance for doubtful accounts (2,104,320 ) (2,870,818 ) Trade accounts receivable, net $ 8,514,466 $ 9,237,743 For the three months ended September 30, 2015 and 2014, $31,541 and $64,636 in accounts receivable were directly written off respectively. For the six months ended September 30, 2015 and 2014, $91,873 and $129,494 in accounts receivable were directly written off respectively.

Other Current Assets

Other Current Assets	6 Months Ended
	Sep. 30, 2015
Other Current Assets [Abstract]
OTHER CURRENT ASSETS	Note 4 – OTHER CURRENT ASSETS Other current assets consisted of the following: September 30, March 31, Prepaid rental expenses (1) $ 1,058,852 $ 1,712,018 Prepaids and other current assets 470,273 488,820 Total $ 1,529,125 $ 2,200,838 (1) Represents store rental expenses that were usually prepaid and amortized over the prepayment period.

Property and Equipment

Property and Equipment	6 Months Ended
	Sep. 30, 2015
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	Note 5 – PROPERTY AND EQUIPMENT Property and equipment consisted of the following: September 30, March 31, Building $ 1,685,509 $ 1,751,986 Leasehold improvements 12,375,652 12,792,714 Farmland development cost 1,880,016 1,954,165 Office equipment and furniture 5,757,427 5,949,193 Motor vehicles 643,038 667,428 Total 22,341,643 23,115,486 Less: Accumulated depreciation (13,816,981 ) (13,606,043 ) Impairment* $ (2,359,599 ) (2,452,662 ) Property and equipment, net $ 6,165,063 $ 7,056,781 *The variance of impairment from March 31, 2015 to September 30, 2015 is solely caused by exchange rate variance. Total depreciation expense for property and equipment was $336,225 and $322,362 for the three months ended September 30, 2015 and 2014, respectively, and $748,018 and $816,444 for the six months ended September 30, 2015 and 2014, respectively. There were no fixed assets impaired in the three and six months ended September 30, 2015. For the year ended March 31, 2015, $1,053,765 of fixed assets in Jiuyingtang was impaired due to the estimated fair value being lower than the carrying value.

Advances to Suppliers

Advances to Suppliers	6 Months Ended
	Sep. 30, 2015
Advances to Suppliers [Abstract]
ADVANCES TO SUPPLIERS	Note 6 – ADVANCES TO SUPPLIERS Advances to suppliers consist of deposits with or advances to outside vendors for future inventory purchases. Some of the Company’s vendors require a certain amount of money to be deposited with them as a guarantee that the Company will receive its purchases on a timely basis. This amount is refundable and bears no interest. As of September 30, 2015 and March 31, 2015, advance to suppliers consist of the following: September 30, March 31, Advance to suppliers $ 4,990,008 $ 5,942,866 Less: allowance for doubtful accounts (249,447 ) (1,225,514 ) Advance to suppliers, net $ 4,740,561 $ 4,717,352 For both the three and six months ended September 30, 2015 and 2014, none of the advances to suppliers were written off against previous allowance for doubtful accounts, respectively.

Inventory

Inventory	6 Months Ended
	Sep. 30, 2015
Inventory [Abstract]
INVENTORY	Note 7 – INVENTORY Inventory consisted of finished goods, which were $11,393,972 and $10,538,591 as of September 30, 2015 and March 31, 2015, respectively. The Company constantly monitors its potential obsolete products and is allowed to return products close to expiration dates to its suppliers. Any loss on damaged items is immaterial and will be recognized immediately, As a result, no reserves were made as of September 30, 2015 and March 31, 2015.

Farmland Assets

Farmland Assets	6 Months Ended
	Sep. 30, 2015
Farmland Assets [Abstract]
FARMLAND ASSETS	Note 8 – FARMLAND ASSETS Farmland assets are ginkgo trees planted in 2012 and expected to be harvested and sold in several years. As of September 30, 2015 and March 31, 2015, farmland assets consisted of the following: September 30, March 31, 2015 2015 Farmland assets $ 2,512,304 $ 2,530,558 Less: impairments* (794,850 ) (826,199 ) Farmland assets, net $ 1,717,454 $ 1,704,359 * The estimated fair value is estimated to be lower than its investment value in fiscal 2014 and 2015. The slight decrease in the impairment amount from March 31, 2015 to September 30, 2015 is caused by exchange rate variance.

Long Term Deposits, Landlords

Long Term Deposits, Landlords	6 Months Ended
	Sep. 30, 2015
Long Term Deposits, Landlords [Abstract]
LONG TERM DEPOSITS, LANDLORDS	Note 9 – LONG TERM DEPOSITS, LANDLORDS Long term deposits were $2,485,977 and $2,584,025 as of September 30, 2015 and March 31, 2015, respectively. Long term deposits are money deposited with or advanced to landlords for securing retail store leases for which the Company does not anticipate applying or being returned within the next twelve months. Most of the Company’s landlords require a minimum of nine months’ rent being paid upfront plus additional deposits.

Other Noncurrent Assets

Other Noncurrent Assets	6 Months Ended
	Sep. 30, 2015
Other Noncurrent Assets [Abstract]
OTHER NONCURRENT ASSETS	Note 10 – OTHER NONCURRENT ASSETS Other noncurrent assets consisted of prepayment for lease of land use right, which were $2,631,030 and $2,734,798 as of September 30, 2015 and March 31, 2015, respectively. The prepayment for lease of land use right is a payment made to a local government in connection with entering into a 30-year operating land lease agreement. The land is currently used to cultivate Ginkgo trees. This prepayment includes a deposit of $1,100,400, which will be refundable on the due date. Based on expected output from planted Gingko trees such as expected fruit production and tree market value, the fair value of the lease prepayment was lower than carrying cost. As a result, the Company recorded impairment on the lease prepayment. The amortization of the prepayment for the lease of land use right was approximately $17,438 and $16,761 for the three months ended September 30, 2015 and 2014, respectively. The amortization of the prepayment for the lease of land use right was approximately $33,387 and $33,517 for the six months ended September 30, 2015 and 2014, respectively. The Company’s amortizations of the prepayment for lease of land use right for the next five years and thereafter are as follows: Years ending September 30, Amount 2016 $ 66,775 2017 66,775 2018 66,775 2019 66,775 2020 66,775 Thereafter 1,196,755

Intangible Assets

Intangible Assets	6 Months Ended
	Sep. 30, 2015
Intangible Assets [Abstract]
INTANGIBLE ASSETS	Note 11 – INTANGIBLE ASSETS Net intangible assets consisted of the following at: September 30, March 31, License (1) $ 1,510,692 $ 1,570,274 Goodwill (1) 22,727 23,623 Land use rights (2) 1,532,944 1,593,403 Software 458,433 477,302 Total other intangible assets 3,524,796 3,664,602 Less: accumulated amortization (518,150 ) (522,599 ) Intangible assets, net $ 3,006,646 $ 3,142,003 Amortization expense of intangibles amounted to $7,808 and $7,864 for the three months ended September 30, 2015 and 2014, respectively, and $15,821 and $15,883 for the six months ended September 30, 2015 and 2014, respectively. (1) As of September 30, 2015, the intangible assets with indefinite life consisted of the following, which were generated through the acquisition of Sanhao Pharmacy. Preliminary Currency translation adjustment Net carrying Licenses* $ 1,566,046 $ (55,354 ) $ 1,510,692 Goodwill on acquisition of Sanhao Pharmacy 23,560 (833 ) 22,727 $ 1,589,606 $ (56,187 ) $ 1,533,419 * This represents the fair value of the licenses of insurance applicable drugstores acquired from Sanhao Pharmacy. The licenses allow patients to pay by the insurance card at stores and the stores can get reimbursed from the Human Resource and Social Security Department of Hangzhou City. (2) In July 2013, the Company purchased the land use right of a plot of farmland in Lin’An, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as our farming business in Lin’An has not grown, the Company does not expect completion of the plant in near future.

Notes Payable

Notes Payable	6 Months Ended
	Sep. 30, 2015
Notes Payable [Abstract]
NOTES PAYABLE	Note 12 – NOTES PAYABLE The Company has credit facilities with Hangzhou United Bank (“HUB”), Bank of Hangzhou (“BOH”) and Industrial and Commercial Bank of China (“ICBC”) that provided working capital in the form of the following bank acceptance notes at September 30, 2015 and March 31, 2015: Origination Maturity September 30, March 31, Beneficiary Endorser date date 2015 2015 Jiuzhou Pharmacy(1) HUB 08/05/14 08/04/15 - 1,634,000 Jiuzhou Pharmacy(1) HUB 10/09/14 04/09/15 - 784,320 Jiuzhou Pharmacy(1) HUB 10/09/14 04/09/15 - 1,187,918 Jiuzhou Pharmacy(1) HUB 12/05/14 06/05/15 - 1,329,651 Jiuzhou Pharmacy(1) HUB 12/26/14 06/26/15 - 1,601,320 Jiuzhou Pharmacy(1) HUB 03/04/15 09/04/15 - 1,470,600 Jiuzhou Pharmacy(1) HUB 03/13/14 09/13/15 - 604,580 Jiuzhou Pharmacy(2) BOH 11/06/14 05/06/15 - 2,908,520 Jiuzhou Pharmacy(2) BOH 02/09/15 08/09/15 - 1,993,480 Jiuzhou Pharmacy(3) ICBC 12/26/14 06/25/15 - 2,238,580 Jiuzhou Pharmacy(1) HUB 04/08/15 10/08/15 1,587,720 - Jiuzhou Pharmacy(3) ICBC 04/10/15 10/09/15 436,859 - Jiuzhou Pharmacy(1) HUB 05/15/15 11/15/15 1,502,832 - Jiuzhou Pharmacy(2) BOH 06/04/15 12/04/15 2,326,560 - Jiuzhou Pharmacy(1) HUB 06/29/15 12/29/15 2,431,884 - Jiuzhou Pharmacy(1) HUB 04/22/15 04/21/16 1,572,000 - Jiuzhou Pharmacy(1) HUB 04/29/15 04/28/16 3,379,800 - Jiuzhou Pharmacy(1) HUB 08/05/15 02/05/16 1,782,648 - Jiuzhou Pharmacy(1) HUB 09/06/15 03/05/16 1,902,765 - Total $ 16,923,068 $ 15,752,969 (1) As of March 31, 2015, the Company had $8,612,389 (RMB52,707,400) of notes payable from HUB. The Company is required to hold restricted cash of $4,763,309 (RMB 29,151,220) with HUB as collateral against these bank notes. As of September 30, 2015, the Company had $14,159,649 (RMB 90,074,100) of notes payable from HUB. The Company is required to hold restricted cash of $10,452,421 (RMB66,491,230) with HUB as collateral against these bank notes. (2) As of March 31, 2015, the Company had $4,902,000 (RMB30,000,000) of notes payable from BOH. The land use right of the farmland in Lin’An, Hangzhou is pledged as collateral for these bank acceptance notes (see Note 12). The Company is required to hold restricted cash of $2,287,600 (RMB 14,000,000) with BOH as collateral against these bank notes. As of September 30, 2015, the Company had $2,326,560 (RMB 14,800,000) of notes payable from BOH. The land use right of the farmland in Lin’An, Hangzhou is pledged as collateral for these bank acceptance notes (see Note 12). The Company is required to hold restricted cash of $1,068,960 (RMB 6,800,000) with BOH as collateral against these bank notes. (3) As of March 31, 2015, the Company had $2,238,580 (RMB 13,700,000) of notes payable from ICBC, with restricted cash of $671,574 (RMB 4,110,000) held at the bank. As of September 30, 2015, the Company had $436,859 (RMB 2,779,000) of notes payable from ICBC, with restricted cash of $131,058 (RMB833,700) held at the bank. As of September 30, 2015, the Company had a credit line of approximately $9.13 million in the aggregate from HUB, BOH and ICBC. By putting up the restricted cash of $12.76 million deposited in the banks, the total credit line was $21.89 million. As of September 30, 2015, the Company had approximately $16.92 million of bank notes payable and approximately $1.51 million bank credit line was still available for further borrowing. The bank notes are also secured by buildings owned by the Company’s major shareholders, land use rights of Jiutong Medical, a shop of Jiuzhou Pharmacy, guaranteed by Jiuxin Medical and guaranteed by Zhejiang JinQiao Guarantee Company. At September 30, 2015, the fair value of the Company’s notes payable was estimated, using Level 2 inputs, at $16,630,964 compared to a carrying amount of $16,923,068. At March 31, 2015, the fair value of the Company’s notes payable was estimated, using Level 2 inputs, at $15,743,000 compared to a carrying amount of $15,752,969. The fair values were estimated using an income approach by applying market interest rates for comparable instruments.

Taxes

Taxes	6 Months Ended
	Sep. 30, 2015
Taxes [Abstract]
TAXES	Note 13 – TAXES Income tax For the three and six months ended September 30, 2015 and 2014, the income tax provisions were as follow: Three months ended Six months ended 2015 2014 2015 2014 Income tax $ (38,062 ) $ 22,680 $ 44,125 $ 38,821 The Company is subject to income taxes on an entity basis on income arising in or derived from the tax jurisdiction in which each entity is domiciled. Jo-Jo Drugstores Entity Income Tax Jurisdiction United States Renovation Hong Kong, PRC All other entities Mainland, PRC The following table reconciles the U.S. statutory tax rates with the Company's effective tax rate for the three and six months ended September 30, 2015 and 2014: Foreign income not recognized in the U.S. (34.0) (34.0) (34.0) (34.0) For the three months For the six months ended September 30, ended September 30, 2015 2014 2015 2014 U.S. Statutory rates 34 .0 % 34 .0 % 34.0 % 34.0 % China income taxes 25.0 25.0 25.0 25.0 Change in valuation allowance (1) (25.0 ) (117.2 ) (25.0 ) (29.9 ) Non-deductible expenses-permanent difference (2) (5.8 ) (61.8 ) (27.9 ) (6.3 ) Effective tax rate (5.8 )% (154.0 )% 27.9 % (11.2 )% (1) It represents non-taxable expense reversal due to overall decrease in allowance for accounts receivables and advance to suppliers. (2) The 5.8% and (61.8)% rate adjustments for the three months ended September 30, 2015 and 2014, and the (27.9)% and (6.3)% rate adjustments for the six months ended September 30, 2015 and 2014 represents expenses primarily included stock option expense, legal, accounting and other expenses incurred by the Company that were not deductible for PRC income tax. Jo-Jo Drugstores is incorporated in the U.S. and incurred a net operating loss for income tax purposes for the three and six months ended September 30, 2015 and 2014. As of September 30, 2015, the estimated net operating loss carry forwards for U.S. income tax purposes amounted to $1,503,000 which may be available to reduce future years’ taxable income. These carry forwards will expire, if not utilized by 2032. Management believes that the realization of the benefits arising from this loss appears to be uncertain due to the Company’s limited operating history and continuing losses for U.S. income tax purposes. Accordingly, the Company has provided a 100% valuation allowance at September 30, 2015. There was no net change in the valuation allowance for the three and six months ended September 30, 2015 and 2014. Management reviews this valuation allowance periodically and makes adjustments as necessary. Taxes payable at September 30, 2015 and March 31, 2015 consisted of the following: September 30, March 31, VAT $ 380,254 $ 301,149 Income tax 7,556 8,007 Others 41,521 18,955 Total taxes payable $ 429,331 $ 328,111 The Company has adopted ASC Topic 740-10-05, Income Taxes. To date, the adoption of this interpretation has not impacted the Company’s financial position, results of operations, or cash flows. The Company performed self-assessment and the Company’s liability for income taxes includes the liability for unrecognized tax benefits, interest and penalties which relate to tax years still subject to review by taxing authorities. Audit periods remain open for review until the statute of limitations has passed, which in the PRC is usually 5 years. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of September 30, 2015 and March 31, 2015, management considered that the Company had no uncertain tax positions affecting its consolidated financial position and results of operations or cash flows, and will continue to evaluate for any uncertain position in future. There are no estimated interest costs and penalties provided in the Company’s consolidated financial statements for the three months and six months ended September 30, 2015 and 2014, respectively. The Company’s tax positions related to open tax years are subject to examination by the relevant tax authorities and the major one is the China Tax Authority.

Postretirement Benefits

Postretirement Benefits	6 Months Ended
	Sep. 30, 2015
Postretirement Benefits [Abstract]
POSTRETIREMENT BENEFITS	Note 14 – POSTRETIREMENT BENEFITS Regulations in the PRC require the Company to contribute to a defined contribution retirement plan for all permanent employees. The contribution for each employee is based on a percentage of the employee’s current compensation as required by the local government. The Company contributed $245,394 and $209,773 in employment benefits and pension for the three months ended September 30, 2015 and 2014, respectively, and $468,405 and $400,271 in employment benefits and pension for the six months ended September 30, 2015 and 2014, respectively.

Related Party Transactions and

Related Party Transactions and Arrangements	6 Months Ended
	Sep. 30, 2015
Related Party Transactions and Arrangements [Abstract]
RELATED PARTY TRANSACTIONS AND ARRANGEMENTS	Note 15 – RELATED PARTY TRANSACTIONS AND ARRANGEMENTS Amounts payable to related parties are summarized as follows: September 30, March 31, Due to cofounders (1): $ 576,818 $ 576,818 Due to a director and CEO (2): 2,182,756 2,152,922 Total $ 2,759,574 $ 2,729,740 (1) As of September 30, 2015 and March 31, 2015, amount due to cofounders represents contributions from the Owners to Jiuxin Management to enable Jiuxin Management to meet its approved PRC registered capital requirements. (2) Due to foreign exchange restrictions, the Company’s director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States. As of September 30, 2015 and March 31, 2015, notes payable totaling $7,425,201 and $5,790,471 were secured by the personal properties of certain of the Company’s shareholders, respectively. The Company leases from Mr. Lei Liu a retail space which expires in September 2015. Rent expense amounted to $23,940 and $24,350 for the three months ended September 30, 2015 and 2014, respectively, and $48,510 and $48,692 for the six months ended September 30, 2015 and 2014. The rent for the three months ended September 30, 2015 has not been paid to Mr. Liu as of September 30, 2015.

Warrants Liabilities

Warrants Liabilities	6 Months Ended
	Sep. 30, 2015
Warrants Liabilities [Abstract]
WARRANTS LIABILITIES	Note 16 – WARRANTS LIABILITIES On September 26, 2013, as annual compensation for its financial advisory service, the Company issued a warrant to a financial consulting firm to purchase up to 150,000 shares of common stock at $1.20 per share. The warrant is exercisable from September 26, 2013 to September 25, 2016. The warrant does not trade in an active securities market, and as such, the Company estimates its fair value using the Black-Scholes Model on the date that the warrant was originally issued and as of September 30, 2015 using the following assumptions: Common Stock September 30, Stock price $ 1.82 Exercise price $ 1.20 Annual dividend yield 0 % Expected term (years) 0.99 Risk-free interest rate 0.33 % Expected volatility 105.77 % (1) As of September 30, 2015, the warrant had not been exercised. On September 26, 2013, the issue date of the warrant, the Company classified its fair value as a liability of $33,606. The Company recognized a gain of $200,903 and $158,064 from the change in fair value of the warrant liability for the three and six months ended September 30, 2015, respectively. The Company recognized a loss of $58,318 and a gain of $27,994 from the change in fair value of the warrant liability for the three and six months ended September 30, 2014, respectively.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Sep. 30, 2015
Stockholders' Equity [Abstract]
STOCKHOLDERS' EQUITY	Note 17 – STOCKHOLDERS’ EQUITY Common Stock On July 24, 2015, the Company closed a registered direct offering of 1.2 million shares of common stock at $2.50 per share with gross proceeds of approximately $3 million from its effective shelf registration statement on Form S-3. Stock-based compensation The Company accounts for share-based payment awards granted to employees and directors by recording compensation expense based on estimated fair values. The Company estimates the fair value of share-based payment awards on the date of grant. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the Company’s consolidated statements of operations. Share-based awards are attributed to expense using the straight-line method over the vesting period. The Company determines the value of each option award that contains a market condition using a Monte Carlo Simulation valuation model, while all other option awards are valued using the Black-Scholes valuation model as permitted under ASC 718, Compensation - Stock Compensation. The assumptions used in calculating the fair value of share-based payment awards represent the Company’s best estimates. The Company’s estimates of the fair values of stock options granted and the resulting amounts of share-based compensation recognized may be impacted by certain variables including stock price volatility, employee stock option exercise behaviors, additional stock option modifications, estimates of forfeitures, and the related income tax impact. Stock option On November 18, 2014, the Company granted a total of 967,000 shares of stock options under the Plan to a group of a total of 46 grantees including directors, officers and employees. The exercise price of the stock option is $2.50. The option vests in three years on November 18, 2017, provided that the grantees are still employed by the Company on such a date. The options will be exercisable for five years from the vesting date, or November 18, 2017 until November 17, 2022. For the three and six months ended September 30, 2015, $124,033 and $248,066 was recorded as compensation expense. As of September 30, 2015, there was approximately $1.06 million of total unrecognized compensation costs related to stock option compensation arrangements granted which is expected to be recognized over the remaining weighted-average period of 2.13 years. Warrants In connection with the registered direct offering closed on July 24, 2015, the Company issued to an investor warrants to purchase up to 600,000 shares of common stock at an exercise price of $3.10 per share. The options are exercisable commencing on January 19, 2016 and expire on January 18, 2021. In connection with the Offering, the Company also issued warrants to its placement agent of this Offering, which can purchase an aggregate of up to 6% of the aggregate number of shares of common stock sold in the Offering, i.e. 72,000 shares. These warrants have the same terms as the warrants issued to purchaser in the Offering. The fair value of these shares amounted to $1,231,067 and $147,728, respectively, which are classified as equity at the date of issuance. Terms of warrants 5 years Expected volatility 105.05 % Risk-free interest rate 1.72 % Expected dividend yield - % The Company applied judgment in estimating key assumptions in determining the fair value of the warrants on the date of issuance. The Company used historical data to estimate stock volatilities and expected dividend yield. The risk-free rates are consistent with the terms of the warrants and are based on the United States Treasury yield curve in effect at the time of issuance. Nine months ended September 30, 2015 Nine months ended September 30, 2014 Number Weight average exercise price Number Weight average exercise p rice Outstanding and exercisable at beginning of the period - $ - - $ - Issued during the period 672,000 3.10 - - Exercised during the period - - - - Cancelled or expired during the period - - - - Outstanding and exercisable at end of the period 672,000 $ 3.10 - $ - Range of exercise price - 3.10 - - Statutory reserves Statutory reserves represent restricted retained earnings. Based on their legal formation, the Company is required to set aside 10% of its net income as reported in their statutory accounts on an annual basis to the Statutory Surplus Reserve Fund (the “Reserve Fund”). Once the total amount set aside in the Reserve Fund reaches 50% of the entity’s registered capital, further appropriations become discretionary. The Reserve Fund can be used to increase the entity’s registered capital upon approval by relevant government authorities or eliminate its future losses under PRC GAAP upon a resolution by its board of directors. The Reserve Fund is not distributable to shareholders, as cash dividend or otherwise, except in the event of liquidation. Appropriations to the Reserve Fund are accounted for as a transfer from unrestricted earnings to statutory reserves. During the three and six months ended September 30, 2015 and 2014, the Company did not make appropriations to the statutory reserves. There are no legal requirements in the PRC to fund the Reserve Fund by transfer of cash to any restricted accounts, and the Company does not do so.

Income (Loss) Per Share

Income (Loss) Per Share	6 Months Ended
	Sep. 30, 2015
Income (Loss) Per Share [Abstract]
INCOME (LOSS) PER SHARE	Note 18 – INCOME (LOSS) PER SHARE The Company reports earnings per share in accordance with the provisions of the FASB’s related accounting standard. This standard requires presentation of basic and diluted earnings per share in conjunction with the disclosure of the methodology used in computing such earnings per share. Basic earnings per share excludes dilution, but includes vested restricted stocks and is computed by dividing income available to common stockholders by the weighted average common shares outstanding during the period. Diluted earnings per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock. The following is a reconciliation of the basic and diluted earnings per share computation: Three months ended Six months ended 2015 2014 2015 2014 Net income (loss) attributable to controlling interest $ 151,175 $ (36,193 ) $ 261,786 $ (382,930 ) Weighted average shares used in basic computation 16,537,461 14,981,637 16,096,406 14,700,375 Diluted effect of purchase options and warrants 51,099 - 51,099 - Diluted effect of restricted shares - - - - Weighted average shares used in diluted computation 16,588,559 14,981,637 16,147,505 14,700,375 Income (loss) per share – Basic: Net income (loss) before noncontrolling interest $ 0.01 $ (0.00 ) $ 0.02 $ (0.03 ) Add: Net loss attributable to noncontrolling interest $ - $ - $ - $ - Net income (loss) attributable to controlling interest $ 0.01 $ (0.00 ) $ 0.02 $ (0.03 ) Loss per share – Diluted: Net income (loss) before noncontrolling interest $ 0.01 $ (0.00 ) $ 0.02 $ (0.03 ) Add: Net loss attributable to noncontrolling interest $ - $ - $ - $ - Net loss attributable to controlling interest $ 0.01 $ (0.00 ) $ 0.02 $ (0.03 ) For the three and six months ended September 30, 2015 and 2014, the 967,000 shares underlying employee stocks options and 600,000 shares underlying outstanding purchase options to an investors, and 72,000 shares underlying outstanding purchase option to an investment placement agent were excluded from the calculation of diluted loss per share as the options were anti-dilutive.

Segments

Segments	6 Months Ended
	Sep. 30, 2015
Segments [Abstract]
SEGMENTS	Note 19 – SEGMENTS The Company operates within four main reportable segments: retail drugstores, online pharmacy, drug wholesale and herb farming. The retail drugstores segment sells prescription and over-the-counter (“OTC”) medicines, TCM, dietary supplement, medical devices, and sundry items to retail customers. Online pharmacy sells OTC drugs, dietary supplement, medical devices and sundry items to customers through Alibaba’s Tmall and its own platform all over China. The drug wholesale segment includes supplying the Company’s own retail drugstores with prescription and OTC medicines, TCM, dietary supplement, medical devices and sundry items (which sales have been eliminated as intercompany transactions), and also selling them to other drug vendors and hospitals. The Company’s herb farming segment cultivates selected herbs for sales to other drug vendors. The Company is also involved in online sales and clinic services that do not meet the quantitative thresholds for reportable segments and are included in the retail drugstores segment. The segments' accounting policies are the same as those described in the summary of significant accounting policies. The Company evaluates performance based on profit or loss from operations before interest and income taxes not including nonrecurring gains and losses. The Company's reportable business segments are strategic business units that offer different products and services. Each segment is managed separately because they require different operations and markets to distinct classes of customers. The following table presents summarized information by segment of the continuing operation for the three months ended September 30, 2015: Retail drugstores Online Pharmacy Drug wholesale Herb Total Revenue $ 13,103,135 $ 6,558,407 $ 2,916,084 $ - $ 22,577,626 Cost of goods 10,177,989 5,737,312 2,685,318 - 18,600,619 Gross profit $ 2,925,146 $ 821,095 $ 230,766 $ - $ 3,977,007 Selling expenses 3,230,986 51,462 136,307 - 3,418,755 General and administrative expenses 1,191,832 214,315 (47,827 )* (518,478 ) 839,842 (Loss) income from operations $ (1,497,672 ) $ 555,318 $ 142,286 $ 518,478 ) $ (281,590 ) Depreciation and amortization $ 134,720 $ - $ 130,103 $ 79,209 $ 344,032 Total capital expenditures $ 6,200 $ 690 $ (83 ) $ - $ 6,807 * include the accounts receivable and advance to suppliers allowance reversal of $850,079. The following table presents summarized information of the continuing operations by segment for the three months ended September 30, 2014: Retail Online Drug Herb Total Revenue $ 12,406,038 $ 2,949,391 $ 3,088,636 $ - $ 18,444,065 Cost of goods 10,302,519 2,463,352 2,912,937 - 15,678,808 Gross profit $ 2,103,519 $ 486,039 $ 175,699 $ - $ 2,765,257 Selling expenses 1,795,108 666 138,006 - 1,933,780 General and administrative expenses 1,412,896 155,861 (911,544 )* 88,962 746,175 (Loss) income from operations $ (1,104,485 ) $ 329,512 $ 949,237 $ (88,962 ) $ 85,302 Depreciation and amortization $ 222,829 $ 1,376 $ 24,022 $ 80,081 $ 328,308 Total capital expenditures $ 107,573 $ 3,210 $ 6,106 $ - $ 116,889 * include the accounts receivable and advance to suppliers allowance reversal of $987,383. The following table presents summarized information of the continuing operation by segment for the six months ended September 30, 2015: Retail Online pharmacy Drug Herb Total Revenue $ 25,274,023 $ 12,524,175 $ 6,090,720 $ - $ 43,888,918 Cost of goods 19,215,883 10,681,595 5,638,750 - 35,536,228 Gross profit $ 6,058,140 $ 1,842,580 $ 451,970 $ - $ 8,352,690 Selling expenses 5,805,454 458,712 250,958 - 6,515,124 General and administrative expenses 2,291,554 445,930 (467,225 ) (510,187 ) 1,760,072 (Loss) income from operations $ (2,038,868 ) $ 937,938 $ 668,237 $ 510,187 $ 77,494 Depreciation and amortization $ 329,727 $ - $ 273,609 $ 160,503 $ 763,839 Total capital expenditures $ 93,132 $ 6,669 $ 6,399 $ - $ 106,200 * include the accounts receivable and advance to suppliers allowance reversal of $1,586,818. The following table presents summarized information of the continuing operation by segment for the six months ended September 30, 2014: Retail Online Drug Herb Total Revenue $ 23,001,797 $ 5,521,933 $ 6,379,567 $ - $ 34,903,297 Cost of goods 18,982,408 4,630,716 6,014,297 - 29,627,421 Gross profit $ 4,019,389 $ 891,217 $ 365,270 $ - $ 5,275,876 Selling expenses 3,465,497 666 236,194 3,702,357 General and administrative expenses 2,676,192 299,560 (1,323,439 ) 175,063 1,827,376 (Loss) income from operations $ (2,122,300 ) $ 590,991 $ 1,452,515 $ (175,063 ) $ (253,857 ) Depreciation and amortization $ 492,846 $ 3,538 $ 175,581 $ 160,605 $ 832,570 Total capital expenditures $ 141,800 $ 3,513 $ 76,258 $ - $ 221,571 * include the accounts receivable and advance to suppliers allowance reversal of $1,634,886. The Company does not have long-lived assets located outside the PRC. In accordance with the enterprise-wide disclosure requirements of FASB’s accounting standard, the Company's net revenue from external customers through its retail stores by main products is as follows: Three months ended Six months ended 2015 2014 2015 2014 Prescription drugs $ 4,789,007 $ 4,957,751 $ 9,435,383 $ 9,378,003 Over-the-counter drugs 5,436,301 4,291,738 10,332,993 8,234,531 Nutritional supplements 1,029,519 547,218 1,940,130 1,171,143 Traditional Chinese medicine 1,276,488 1,991,112 2,412,997 3,186,746 Sundry products 341,663 502,724 603,710 859,783 Medical devices 230,157 115,495 548,810 171,591 Total $ 13,103,135 $ 12,406,038 $ 25,274,023 $ 23,001,797 The Company’s net revenue from external customers through online pharmacy by main products is as follows: Three months ended Six months ended 2015 2014 2015 2014 Prescription drugs $ - $ - $ - $ - Over-the-counter drugs 1,730,043 826,755 3,610,327 1,519,598 Nutritional supplements 559,390 191,953 1,073,134 341,893 Traditional Chinese medicine - - - Sundry products 2,587,169 455,521 3,814,123 775,491 Medical devices 1,681,805 1,475,162 4,026,592 2,884,951 Total $ 6,558,407 $ 2,949,391 $ 12,524,175 $ 5,521,933 The Company’s net revenue from external customers through wholesale by main products is as follows: Three months ended Six months ended 2015 2014 2015 2014 Prescription drugs $ 1,808,043 $ 2,362,902 $ 3,711,364 $ 4,261,984 Over-the-counter drugs 1,077,992 611,219 2,274,770 1,948,429 Nutritional supplements 23,346 6,387 43,931 33,949 Traditional Chinese medicine - 80,905 - 89,268 Sundry products 3,482 6,583 6,414 6,777 Medical devices 3,221 20,640 54,240 39,160 Total $ 2,916,084 $ 3,088,636 $ 6,090,720 $ 6,379,567

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Sep. 30, 2015
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	Note 20 – COMMITMENTS AND CONTINGENCIES Operating lease commitments The Company recognizes lease expense on a straight line basis over the term of its leases in accordance with the relevant accounting standards. The Company has entered into various tenancy agreements for its store premises and for the land leased from a local government to farm herbs. The Company’s commitments for minimum rental payments under its leases for the next five years and thereafter are as follows: Periods ending September 30, Retail Online Drug Herb farming Total 2015 $ 3,718,382 $ 200,848 $ 176,010 $ - $ 4,095,240 2016 2,843,385 218,175 150,171 - 3,211,731 2017 2,537,549 165,138 150,171 - 2,852,858 2018 2,034,545 138,619 150,171 - 2,323,335 2019 891,800 138,619 112,628 - 1,143,047 Thereafter 133,332 69,310 - - 202,642 Total rent expense amounted to $1,178,159 and $1,215,232 for the three months ended September 30, 2015 and 2014, respectively, and $2,427,544 and $2,397,776 for the six months ended September 30, 2015 and 2014, respectively.

Subsequent Events

Subsequent Events	6 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	Note 21 – SUBSEQUENT EVENTS In October, the two bank notes of $1,587,720 and $436,859 from HUB and ICBC, respectively, have been paid off.

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2015
Summary of Significant Accounting Policies [Abstract]
Basis of presentation and consolidation	Basis of presentation and consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles (“US GAAP”) for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. These condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s annual report on Form 10-K for the fiscal year ended March 31, 2015 filed with the SEC on June 29, 2015. Operating results for the three and six months ended September 30, 2015 may not be necessarily indicative of the results that may be expected for the full year. The condensed consolidated financial statements include the financial statements of the Company, its subsidiaries and VIEs. All significant inter-company transactions and balances between the Company, its subsidiaries and VIEs are eliminated upon consolidation. Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no effect on net income or cash flows as previously reported.
Consolidation of variable interest entities	Consolidation of variable interest entities In accordance with accounting standards regarding consolidation of variable interest entities, VIEs are generally entities that lack sufficient equity to finance their activities without additional financial support from other parties or whose equity holders lack adequate decision making ability. All VIEs with which the Company is involved must be evaluated to determine the primary beneficiary of the risks and rewards of the VIE. The primary beneficiary is required to consolidate the VIE for financial reporting purposes. The Company has concluded, based on the contractual arrangements, that Jiuzhou Pharmacy (including its subsidiaries and controlled entities), Jiuzhou Clinic and Jiuzhou Service are each a VIE and that the Company’s wholly-owned subsidiary, Jiuxin Management, absorbs a majority of the risk of loss from the activities of these companies, thereby enabling the Company, through Jiuxin Management, to receive a majority of their respective expected residual returns. Additionally, as Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service are under common control, the consolidated financial statements have been prepared as if the transactions had occurred retroactively as to the beginning of the reporting period of these consolidated financial statements. Control and common control are defined under the accounting standards as “an individual, enterprise, or immediate family members who hold more than 50 percent of the voting ownership interest of each entity.” Because the Owners collectively own 100% of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and have agreed to vote their interests in concert since the establishment of each of these three companies as memorialized the Voting Rights Proxy Agreement, the Company believes that the Owners collectively have control and common control of the three companies. Accordingly, the Company believes that Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service were constructively held under common control by Jiuxin Management as of the time the Contractual Agreements were entered into, establishing Jiuxin Management as their primary beneficiary. Jiuxin Management, in turn, is owned by Renovation, which is owned by the Company.
Risks and Uncertainties	Risks and Uncertainties The operations of the Company are located in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may be influenced by political, economic, and legal environments in the PRC, as well as by the general state of the PRC economy. The Company’s operations in the PRC are subject to special considerations and significant risks not typically associated with companies in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environment and foreign currency exchange. The Company’s results may be adversely affected by changes in the political, regulatory and social conditions in the PRC. Although the Company has not experienced losses from these situations and believes that it is in compliance with existing laws and regulations including its organization and structure disclosed in Note 1, this may not be indicative of future results. The Company has significant cash deposits with suppliers in order to obtain and maintain inventory. The Company’s ability to obtain products and maintain inventory at existing and new locations is dependent upon its ability to post and maintain significant cash deposits with its suppliers. In the PRC, many vendors are unwilling to extend credit terms for product sales that require cash deposits to be made. The Company does not generally receive interest on any of its supplier deposits, and such deposits are subject to loss as a result of the creditworthiness or bankruptcy of the party who holds such funds, as well as the risk from illegal acts such as conversion, fraud, theft or dishonesty associated with the third party. If these circumstances were to arise, the Company would find it difficult or impossible, due to the unpredictability of legal proceedings in China, to recover all or a portion of the amount on deposit with its vendors or landlords. Members of the current management team own controlling interests in the Company and are also the Owners of the VIEs in the PRC. The Company only controls the VIEs through contractual arrangements which obligate it to absorb the risk of loss and to receive the residual expected returns. As such, the controlling shareholders of the Company and the VIEs could cancel these agreements or permit them to expire at the end of the agreement terms, as a result of which the Company would not retain control of the VIEs.
Use of estimates	Use of estimates The preparation of unaudited condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The significant estimates made in the preparation of the accompanying unaudited condensed consolidated financial statements relate to the assessment of the carrying values of accounts receivable, advances to suppliers and related allowance for doubtful accounts, useful lives of property and equipment, inventory reserve and fair value of its purchase option derivative liability. Because of the use of estimates inherent in the financial reporting process, actual results could materially differ from those estimates.
Fair value measurements	Fair value measurements The Company has adopted ASC Topic 820, Fair Value Measurement and Disclosure, which defines fair value, establishes a framework for measuring fair value in GAAP, and expands disclosures about fair value measurements. It does not require any new fair value measurements, but provides guidance on how to measure fair value by providing a fair value hierarchy used to classify the source of the information. It establishes a three-level valuation hierarchy of valuation techniques based on observable and unobservable inputs, which may be used to measure fair value and include the following: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Classification within the hierarchy is determined based on the lowest level of input that is significant to the fair value measurement. The Company's financial assets and liabilities, which include financial instruments as defined by ASC 820, include cash and cash equivalents, accounts receivable, accounts payable, long-term debt and derivatives. The carrying amounts of cash and cash equivalents, financial assets available for sales, accounts receivable, notes receivables, and accounts payable are a reasonable approximation of fair value due to the short maturities of these instruments (Level 1). The carrying amount of notes payable approximates fair value based on borrowing rates of similar bank loan currently available to the Company (Level 2) (See Note 12). The carrying amount of the Company's warrants is recorded at fair value and is determined based on observable inputs that are corroborated by market data (Level 2). As of September 30, 2015 and March 31, 2015, the fair values of our derivative instruments that were carried at fair value. (See Note 16)
Revenue recognition	Revenue recognition Revenue from sales of prescription medicine at the drugstores is recognized when the prescription is filled and the customer picks up and pays for the prescription. Revenue from sales of other merchandise at the drugstores is recognized at the point of sale, which is when a customer pays for and receives the merchandise. Usually the majority of our merchandise such as prescription and OTC drugs are not allowed to be returned after the customers leave the counter. Return of other products such as sundry products are minimal. Sales of drugs reimbursed by the local government medical insurance agency and receivables from the agency are recognized when a customer pays for the drugs at a store. Based on historical experience, a reserve for potential loss from denial of reimbursement on certain unqualified drugs is made to the receivables from the government agency. Revenue from medical services is recognized after the service has been rendered to a customer. Revenue from online pharmacy sales is recognized when merchandise is shipped to customers. While most deliveries take one day, certain deliveries may take longer depending on a customer’s location. Any loss caused in a shipment will be reimbursed by the Company’s courier company. Our sales policy allows return of certain merchandises without reasons within seven days after customer’s receipts of merchandise. A proper sales reserve is made to account for the potential loss from returns from customers. Historically, sales returns seven days after merchandise receipts have been minimal. Revenue from sales of merchandise to non-retail customers is recognized when the following conditions are met: (1) persuasive evidence of an arrangement exists (sales agreements and customer purchase orders are used to determine the existence of an arrangement); (2) delivery of goods has occurred and risks and benefits of ownership have been transferred, which is when the goods are received by the customer at its designated location in accordance with the sales terms; (3) the sales price is fixed or determinable; and (4) collectability is probable. Historically, sales returns have been minimal. The Company’s revenue is net of value added tax (“VAT”) collected on behalf of PRC tax authorities in respect to the sales of merchandise. VAT collected from customers, net of VAT paid for purchases, is recorded as a liability in the accompanying consolidated balance sheets until it is paid to the relevant PRC tax authorities.
Restricted cash	Restricted cash The Company’s restricted cash consists of cash in a bank as security for its notes payable. The Company has notes payable outstanding with the bank and is required to keep certain amounts on deposit that are subject to withdrawal restrictions. The notes payable are generally short term in nature due to their short maturity period of six to nine months; thus, restricted cash is classified as a current asset.
Accounts receivable	Accounts receivable Accounts receivable represents the following: (1) amounts due from banks relating to retail sales that are paid or settled by the customers’ debit or credit cards, (2) amounts due from government social security bureaus and commercial health insurance programs relating to retail sales of drugs, prescription medicine, and medical services that are paid or settled by the customers’ medical insurance cards, (3) amounts due from non-bank third party payment instruments such as Alipay from certain e-commerce platforms and (4) amounts due from non-retail customers for sales of merchandise. Accounts receivable are recorded at net realizable value consisting of the carrying amount less an allowance for uncollectible accounts, as necessary. In the Company’s retail business, accounts receivable mainly consist of reimbursements due from the government insurance bureaus and commercial health insurance programs and are usually collected within two or three months. The Company directly writes off delinquent account balances, which is determined to be uncollectible after confirming with the appropriate bureau or program each month. Additionally, the Company also makes estimated reserves on related outstanding accounts receivable based on historical trend. In the Company’s online pharmacy business, accounts receivables primarily consist of amounts due from non-bank third party payment instruments such as Alipay from certain e-commerce platforms. To purchase pharmaceutical products from the e-commerce platforms such as Tmall, customers are required to pay to certain non-bank third party payment instruments such as Alipay, which, in turn, will reimburse the Company within seven days to a month. Except for customer returns of sold products, the receivables from these payments instruments are rarely uncollectible. In its wholesale business, the Company uses the aging method to estimate the allowance for anticipated uncollectible receivable balances. Under the aging method, bad debt percentages are determined by management, based on historical experience and the current economic climate, are applied to customers’ balances categorized by the number of months the underlying invoices have remained outstanding. At each reporting period, the allowance balance is adjusted to reflect the amount computed as a result of the aging method. When facts subsequently become available to indicate that the allowance provided requires an adjustment, a corresponding adjustment is made to the allowance account as a change in estimate.
Inventories	Inventories Inventories are stated at the lower of cost or market value. Cost is determined by the first in first out (FIFO) method. Market value is the lower of replacement cost or net realizable value. The Company carries out physical inventory counts on a monthly basis at each store and warehouse. The Company periodically reviews its inventory and records write-downs to inventories for shrinkage losses and damaged merchandise that are identified. The Company provides a reserve for estimated inventory obsolescence or excess quantities on hand equal to the difference , if any, between the cost of the inventory and its estimated realizable value.
Farmland assets	Farmland assets Herbs that the Company farms are recorded at their costs, which includes direct costs such as seed selection, fertilizer, and labor costs that are spent in growing herbs on the leased farmland, and indirect costs such as amortization of farmland development costs. Since April 2014, amortization of farmland development costs has been expensed instead of allocated into inventory due to unpredictable future market value of planted gingko trees. All related costs described in the above are accumulated until the time of harvest and then allocated to harvested herbs when they are sold.
Property and equipment	Property and equipment Property and equipment are stated at cost, net of accumulated depreciation or amortization. Depreciation is calculated on the straight-line method over the estimated useful lives of the assets, taking into consideration the assets’ estimated residual value. Leasehold improvements are amortized over the shorter of lease term or remaining lease period of the underlying assets. Following are the estimated useful lives of the Company’s property and equipment: Estimated Useful Life Leasehold improvements 3-10 years Motor vehicles 3-5 years Office equipment & furniture 3-5 years Buildings 35 years Maintenance, repairs and minor renewals are charged to expenses as incurred. Major additions and betterment to property and equipment are capitalized.
Intangibles	Intangibles Intangible assets are acquired individually or as part of a group of assets, and are initially recorded at their fair value. The cost of a group of assets acquired in a transaction is allocated to the individual assets based on their relative fair values. The estimated useful lives of the Company’s intangible assets are as follows: Estimated Useful Life Land use right 50 years Software 3 years The Company evaluates intangible assets for impairment whenever events or changes in circumstances indicate that the assets might be impaired.
Impairment of long-lived assets	Impairment of long lived assets The Company evaluates long lived tangible and intangible assets for impairment, whenever events or changes in circumstances indicate that the carrying value may not be recoverable from its estimated future cash flows. Recoverability is measured by comparing the assets’ net book value to the related projected undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections, market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset is considered impaired, and a second test is performed to measure the amount of impairment loss. There was no additional impairment occurred during fiscal 2015.
Notes payable	Notes payable During the normal course of business, the Company regularly issues bank acceptance bills as a payment method to settle outstanding accounts payables with various material suppliers. The Company records such bank acceptance bills as notes payable. Such notes payable are generally short term in nature due to their short maturity period of six to nine months.
Income taxes	Income taxes The Company records income taxes pursuant to the accounting standards for income taxes. These standards require the recognition of deferred income tax liabilities and assets for the expected future tax consequences of temporary differences between income tax basis and financial reporting basis of assets and liabilities. Provision for income taxes consists of taxes currently due and the net change in deferred taxes. A valuation allowance is recognized if it is more likely than not that some portion, or all of, a deferred tax asset will not be realized. The accounting standards clarify the accounting and disclosure requirements for uncertain tax positions and prescribe a recognition threshold and measurement attribute for recognition and measurement of a tax position taken or expected to be taken in a tax return. The accounting standards also provide guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures, and transition. No significant penalties, uncertain tax provisions or interest relating to income taxes were incurred during the periods ended September 30, 2015 and 2014.
Value added tax	Value added tax Sales revenue represents the invoiced value of goods, net of VAT. All of the Company’s products are sold in the PRC and are subjected to a VAT on the gross sales price. The VAT rates range up to 17%, depending on the type of products sold. The VAT may be offset by VAT paid by the Company on raw materials and other materials included in the cost of producing or acquiring its finished products. The Company recorded a VAT payable net of payments in the accompanying financial statements.
Stock based compensation	Stock based compensation The Company follows the provisions of ASC 718, “Compensation — Stock Compensation,” which establishes accounting standards for non-employee and employee stock-based awards. Under the provisions of ASC 718, the fair value of stock issued is used to measure the fair value of services received as the Company believes such approach is a more reliable method of measuring the fair value of the services. For non-employee stock-based awards, fair value is measured based on the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is calculated and then recognized as compensation expense over the requisite performance period. For employee stock-based awards, share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense with graded vesting on a straight–line basis over the requisite service period for the entire award.
Advertising and promotion costs	Advertising and promotion costs Advertising and promotion costs are expensed as incurred and amounted to $134,887 and $81,321 for three months ended September 30, 2015 and 2014, respectively, and $198,053 and $131,239 for the six months ended September 30, 2015 and 2014, respectively. Such costs consist primarily of print and promotional materials such as flyers to local communities.
Operating leases	Operating leases The Company leases premises for retail drugstores, offices and wholesale warehouse under non-cancelable operating leases. Operating lease payments are expensed over the term of lease. A majority of the Company’s retail drugstore leases have a 3 to 8 year term with a renewal option upon the expiration of the lease; the wholesale warehouse lease has a 10-year term with a renewal option upon the expiration of the lease. The Company has historically been able to renew a majority of its drugstores leases. Under the terms of the lease agreements, the Company has no legal or contractual asset retirement obligations at the end of the lease. In addition, land leased from the government is amortized on a straight-line basis over a 30-year term.
Foreign currency translation	Foreign currency translation The Company uses the United States dollar (“U.S. dollars” or “USD”) for financial reporting purposes. The Company’s subsidiaries and VIEs maintain their books and records in their functional currency the Renminbi (“RMB”), the currency of the PRC. In general, for consolidation purposes, the Company translates the assets and liabilities of its subsidiaries and VIEs into U.S. dollars using the applicable exchange rates prevailing at the balance sheet date, and the statements of income and cash flows are translated at average exchange rates during the reporting period. As a result, amounts related to assets and liabilities reported on the statement of cash flows will not necessarily agree with changes in the corresponding balances on the balance sheet. Equity accounts are translated at historical rates. Adjustments resulting from the translation of the financial statements of the subsidiaries and VIEs are recorded as accumulated other comprehensive income. The balance sheet amounts, with the exception of equity, at September 30, 2015 and March 31, 2015 were translated at 1 RMB to $0.1572 USD and at 1 RMB to $0.1634 USD, respectively. The average translation rates applied to income and cash flow statement amounts for the six months ended September 30, 2015 and 2014 were at 1 RMB to $0.1617 USD and at 1 RMB to $0.1623 USD, respectively.
Concentrations and credit risk	Concentrations and credit risk Certain financial instruments, which subject the Company to concentration of credit risk, consist of cash and restricted cash. The Company has cash balances at financial institutions located in Hong Kong and PRC. Balances at financial institutions in Hong Kong may, from time to time, exceed Hong Kong Deposit Protection Board’s insured limits. Since March 31, 2015, balances at financial institutions and state-owned banks within the PRC are covered by insurance up to (USDRMB 500,000 per bank. As of September 30, 2015 and March 31, 2015, the Company had deposits totaling $16,404,370 and $12,563,579 that were covered by such an insurance in China, respectively. To date, the Company has not experienced any losses in such accounts. For the three months ended September 30, 2015, the two largest vendors accounted for 24.5% of the Company’s total purchases and one vendor accounted for 18.2% of total advances to suppliers. For the three months ended September 30, 2014, the two largest vendors accounted for 24.5% of the Company’s total purchases and one vendor accounted for 18.2% of total advances to suppliers. For the six months ended September 30, 2015, the two largest vendors accounted for 25.3% of the Company’s total purchases and one vendor accounted for 18.2% of total advances to suppliers. For the six months ended September 30, 2014, the two largest vendors accounted for 25.3% of the Company’s total purchases and one vendor accounted for 18.2% of total advances to suppliers. For the three months ended September 30, 2015, no customer accounted for more than 10% of the Company’s total sales or accounts receivable. For the three months ended September 30, 2014, no customer accounted for more than 10% of the Company’s total sales or accounts receivable. For the six months ended September 30, 2015, no customer accounted for more than 10% of the Company’s total sales or accounts receivable. For the six months ended September 30, 2014, no customer accounted for more than 10% of the Company’s total sales or accounts receivable.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2015-10, “Technical Corrections and Improvements” (“ASU 2015-10”). The amendments in ASU 2015-10 cover a wide range of Topics in the Accounting Standards Codification (the “ASC”). The amendments in ASU 2015-10 represent changes to clarify the ASC, correct unintended application of guidance, or make minor improvements to the ASC that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. Additionally, some of the amendments will make the ASC easier to understand and easier to apply by eliminating inconsistencies, providing needed clarifications, and improving the presentation of guidance in the ASC. Transition guidance varies based on the amendments in ASU 2015-10. The amendments in ASU 2015-10 that require transition guidance are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. All other amendments will be effective upon the issuance of ASU 2015-10. We are currently in the process of evaluating the impact of the adoption of ASU 2015-02 on our consolidated financial statements. In July 2015, the FASB issued ASU No. 2015-11, “Inventory (Topic 330): Simplifying the Measurement of Inventory” (“ASU 2015-11”). The amendments in this update require an entity to measure inventory within the scope of ASU 2015-11 (the amendments in ASU 2015-11 do not apply to inventory that is measured using last-in, first-out or the retail inventory method. The amendments apply to all other inventory, which includes inventory that is measured using first-in, first-out or average cost) at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Subsequent measurement is uncharged for inventory measured using last-in, first-out or the retail inventory method. The amendments in ASU 2015-11 more closely align the measurement of inventory in U.S. GAAP with the measurement of inventory in International Financial Reporting Standards (“IFRS”). ASU 2015-11 is effective for public business entities for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The amendments in ASU 2015-11 should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. We are currently in the process of evaluating the impact of the adoption of ASU 2015-02 on our consolidated financial statements. In August 2015, the FASB issued ASU 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which defers the effective date of ASU 2014-09 for all entities by one year. Public business entities, certain not-for-profit entities, and certain employee benefit plans should apply the guidance in ASU 2014-09 to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Currently, the Company is evaluating the impact of our pending adoption of ASU 2014-09 and ASU 2015-14 on its consolidated financial statements and has not yet determined the method by which it will adopt the standard in year 2018.

Description of Business and O28

Description of Business and Organization (Tables)	6 Months Ended
	Sep. 30, 2015
Description of Business and Organization [Abstract]
Schedule of consolidated financial statements activities	Entity Name Background Ownership Renovation HK ● Incorporated in Hong Kong SAR on September 2, 2008 100% Jiuxin Management ● Established in the PRC on October 14, 2008 ● Deemed a wholly foreign owned enterprise (“WFOE”) under PRC law ● Registered capital of $4.5 million fully paid 100% Shouantang Technology ● Established in the PRC on July 16, 2010 by Renovation with registered capital of $20 million ● Registered capital requirement reduced by the SAIC to $11 million in July 2012 and is fully paid ● Deemed a WFOE under PRC law ● Invests and finances the working capital of Quannuo Technology 100% Qianhong Agriculture ● Established in the PRC on August 10, 2010 by Jiuxin Management ● Registered capital of RMB 10 million fully paid ● Carries out herb farming business 100% Quannuo Technology ● Established in the PRC on July 7, 2009 ● Registered capital of RMB 10 million fully paid ● Acquired by Shouantang Technology in November 2010 ● Operates the Company’s online pharmacy website and provide software and technical support 100% Hangzhou Quannuo ● Established in the PRC on July 8, 2010 by Quannuo Technology ● Registered capital of RMB 800,000 fully paid ● Currently has no operation and has closed, pending dissolution 100% Jiuzhou Pharmacy (1) ● Established in the PRC on September 9, 2003 ● Registered capital of RMB 5 million fully paid ● Operates the “Jiuzhou Grand Pharmacy” stores in Hangzhou VIE by contractual arrangements (2) Jiuzhou Clinic (1) ● Established in the PRC as a general partnership on October 10, 2003 ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores VIE by contractual arrangements (2) Jiuzhou Service (1) ● Established in the PRC on November 2, 2005 ● Registered capital of RMB 500,000 fully paid ● Operates a medical clinic adjacent to one of Jiuzhou Pharmacy’s stores VIE by contractual arrangements (2) Jiuxin Medicine ● Established in PRC on December 31, 2003 ● Acquired by Jiuzhou Pharmacy in August 2011 ● Registered capital of RMB 10 million fully paid ● Carries out pharmaceutical distribution services VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy (2) Jiutong Medical ● Established in the PRC on December 20, 2011 by Renovation ● Registered capital of $2.6 million fully paid ● Currently has no operation 100% Shouantang Bio ● Established in the PRC in October, 2014 by Shouantang Technology ● 100% held by Shouantang Technology ● Registered capital of RMB 1,000,000 fully paid ● Sells nutritional supplements under its own brand name VIE by contractual arrangements as a controlled entity of Jiuzhou Service (2) Jianshun ● Established in the PRC in May, 2015 ● 35% held by Jiuzhou Pharmacy ● Manages sales on official website of the online pharmacy VIE by contractual arrangements as a controlled entity of Jiuzhou Pharmacy (2) Jiuyi Technology ● Established in the PRC on September 10, 2015 ● 100% held by Renovation HK ● Technical support to online pharmacy 100% (1) Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service have been under the common control of the three shareholders of Renovation (the “Owners”) since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. Operationally, the Owners have operated these three companies in conjunction with one another since each company’s respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy, as is Shouantang Health as a subsidiary of Jiuzhou Service and Jianshun as a subsidiary of Jiuzhou Pharmacy. (2) To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. As a result of these agreements, which obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for all three companies (as well as one subsidiary of Jiuzhou Pharmacy) as a variable interest entity (“VIE”) under the accounting standards of the Financial Accounting Standards Board (“FASB”). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiary under the control of Jiuzhou Pharmacy (Shouantang Health), are consolidated into the financial statements of the Company.

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Sep. 30, 2015
Summary of Significant Accounting Policies [Abstract]
Schedule of estimated useful lives of property and equipment	Estimated Useful Life Leasehold improvements 3-10 years Motor vehicles 3-5 years Office equipment & furniture 3-5 years Buildings 35 years
Schedule of estimated useful lives of intangible assets	Estimated Useful Life Land use right 50 years Software 3 years

Trade Accounts Receivable (Tabl

Trade Accounts Receivable (Tables)	6 Months Ended
	Sep. 30, 2015
Trade Accounts Receivable [Abstract]
Schedule of trade accounts receivable	September 30, March 31, Accounts receivable $ 10,618,786 $ 12,108,561 Less: allowance for doubtful accounts (2,104,320 ) (2,870,818 ) Trade accounts receivable, net $ 8,514,466 $ 9,237,743

Other Current Assets (Tables)

Other Current Assets (Tables)	6 Months Ended
	Sep. 30, 2015
Other Current Assets [Abstract]
Schedule of other current assets	September 30, March 31, Prepaid rental expenses (1) $ 1,058,852 $ 1,712,018 Prepaids and other current assets 470,273 488,820 Total $ 1,529,125 $ 2,200,838 (1) Represents store rental expenses that were usually prepaid and amortized over the prepayment period.

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Sep. 30, 2015
Property and Equipment [Abstract]
Schedule of property and equipment	September 30, March 31, Building $ 1,685,509 $ 1,751,986 Leasehold improvements 12,375,652 12,792,714 Farmland development cost 1,880,016 1,954,165 Office equipment and furniture 5,757,427 5,949,193 Motor vehicles 643,038 667,428 Total 22,341,643 23,115,486 Less: Accumulated depreciation (13,816,981 ) (13,606,043 ) Impairment* $ (2,359,599 ) (2,452,662 ) Property and equipment, net $ 6,165,063 $ 7,056,781 *The variance of impairment from March 31, 2015 to September 30, 2015 is solely caused by exchange rate variance.

Advances to Suppliers (Tables)

Advances to Suppliers (Tables)	6 Months Ended
	Sep. 30, 2015
Advances to Suppliers [Abstract]
Schedule of advance to suppliers	September 30, March 31, Advance to suppliers $ 4,990,008 $ 5,942,866 Less: allowance for doubtful accounts (249,447 ) (1,225,514 ) Advance to suppliers, net $ 4,740,561 $ 4,717,352

Farmland Assets (Tables)

Farmland Assets (Tables)	6 Months Ended
	Sep. 30, 2015
Farmland Assets [Abstract]
Schedule of farmland assets	September 30, March 31, 2015 2015 Farmland assets $ 2,512,304 $ 2,530,558 Less: impairments* (794,850 ) (826,199 ) Farmland assets, net $ 1,717,454 $ 1,704,359 * The estimated fair value is estimated to be lower than its investment value in fiscal 2014 and 2015. The slight decrease in the impairment amount from March 31, 2015 to September 30, 2015 is caused by exchange rate variance.

Other Noncurrent Assets (Tables

Other Noncurrent Assets (Tables)	6 Months Ended
	Sep. 30, 2015
Other Noncurrent Assets [Abstract]
Schedule of other noncurrent assets	Years ending September 30, Amount 2016 $ 66,775 2017 66,775 2018 66,775 2019 66,775 2020 66,775 Thereafter 1,196,755

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Sep. 30, 2015
Intangible Assets [Abstract]
Schedule of net intangible assets	September 30, March 31, License (1) $ 1,510,692 $ 1,570,274 Goodwill (1) 22,727 23,623 Land use rights (2) 1,532,944 1,593,403 Software 458,433 477,302 Total other intangible assets 3,524,796 3,664,602 Less: accumulated amortization (518,150 ) (522,599 ) Intangible assets, net $ 3,006,646 $ 3,142,003 (1) As of September 30, 2015, the intangible assets with indefinite life consisted of the following, which were generated through the acquisition of Sanhao Pharmacy. (2) In July 2013, the Company purchased the land use right of a plot of farmland in Lin’An, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as our farming business in Lin’An has not grown, the Company does not expect completion of the plant in near future.
Schedule of intangible assets with indefinite life generated through acquisition of Sanhao Pharmacy	Preliminary Currency translation adjustment Net carrying Licenses* $ 1,566,046 $ (55,354 ) $ 1,510,692 Goodwill on acquisition of Sanhao Pharmacy 23,560 (833 ) 22,727 $ 1,589,606 $ (56,187 ) $ 1,533,419 * This represents the fair value of the licenses of insurance applicable drugstores acquired from Sanhao Pharmacy. The licenses allow patients to pay by the insurance card at stores and the stores can get reimbursed from the Human Resource and Social Security Department of Hangzhou City.

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Sep. 30, 2015
Notes Payable [Abstract]
Schedule of credit facilities with bank	Origination Maturity September 30, March 31, Beneficiary Endorser date date 2015 2015 Jiuzhou Pharmacy(1) HUB 08/05/14 08/04/15 - 1,634,000 Jiuzhou Pharmacy(1) HUB 10/09/14 04/09/15 - 784,320 Jiuzhou Pharmacy(1) HUB 10/09/14 04/09/15 - 1,187,918 Jiuzhou Pharmacy(1) HUB 12/05/14 06/05/15 - 1,329,651 Jiuzhou Pharmacy(1) HUB 12/26/14 06/26/15 - 1,601,320 Jiuzhou Pharmacy(1) HUB 03/04/15 09/04/15 - 1,470,600 Jiuzhou Pharmacy(1) HUB 03/13/14 09/13/15 - 604,580 Jiuzhou Pharmacy(2) BOH 11/06/14 05/06/15 - 2,908,520 Jiuzhou Pharmacy(2) BOH 02/09/15 08/09/15 - 1,993,480 Jiuzhou Pharmacy(3) ICBC 12/26/14 06/25/15 - 2,238,580 Jiuzhou Pharmacy(1) HUB 04/08/15 10/08/15 1,587,720 - Jiuzhou Pharmacy(3) ICBC 04/10/15 10/09/15 436,859 - Jiuzhou Pharmacy(1) HUB 05/15/15 11/15/15 1,502,832 - Jiuzhou Pharmacy(2) BOH 06/04/15 12/04/15 2,326,560 - Jiuzhou Pharmacy(1) HUB 06/29/15 12/29/15 2,431,884 - Jiuzhou Pharmacy(1) HUB 04/22/15 04/21/16 1,572,000 - Jiuzhou Pharmacy(1) HUB 04/29/15 04/28/16 3,379,800 - Jiuzhou Pharmacy(1) HUB 08/05/15 02/05/16 1,782,648 - Jiuzhou Pharmacy(1) HUB 09/06/15 03/05/16 1,902,765 - Total $ 16,923,068 $ 15,752,969 (1) As of March 31, 2015, the Company had $8,612,389 (RMB52,707,400) of notes payable from HUB. The Company is required to hold restricted cash of $4,763,309 (RMB 29,151,220) with HUB as collateral against these bank notes. As of September 30, 2015, the Company had $14,159,649 (RMB 90,074,100) of notes payable from HUB. The Company is required to hold restricted cash of $10,452,421 (RMB66,491,230) with HUB as collateral against these bank notes. (2) As of March 31, 2015, the Company had $4,902,000 (RMB30,000,000) of notes payable from BOH. The land use right of the farmland in Lin’An, Hangzhou is pledged as collateral for these bank acceptance notes (see Note 12). The Company is required to hold restricted cash of $2,287,600 (RMB 14,000,000) with BOH as collateral against these bank notes. As of September 30, 2015, the Company had $2,326,560 (RMB 14,800,000) of notes payable from BOH. The land use right of the farmland in Lin’An, Hangzhou is pledged as collateral for these bank acceptance notes (see Note 12). The Company is required to hold restricted cash of $1,068,960 (RMB 6,800,000) with BOH as collateral against these bank notes. (3) As of March 31, 2015, the Company had $2,238,580 (RMB 13,700,000) of notes payable from ICBC, with restricted cash of $671,574 (RMB 4,110,000) held at the bank. As of September 30, 2015, the Company had $436,859 (RMB 2,779,000) of notes payable from ICBC, with restricted cash of $131,058 (RMB833,700) held at the bank.

Taxes (Tables)

Taxes (Tables)	6 Months Ended
	Sep. 30, 2015
Taxes [Abstract]
Schedule of income tax provision	Three months ended Six months ended 2015 2014 2015 2014 Income tax $ (38,062 ) $ 22,680 $ 44,125 $ 38,821
Schedule of income arising in derived from tax jurisdiction which each entity domiciled	Entity Income Tax Jurisdiction Jo-Jo Drugstores United States Renovation Hong Kong, PRC All other entities Mainland, PRC
Schedule of reconciliation of the U.S. statutory tax rates with company's effective tax rate	For the three months For the six months ended September 30, ended September 30, 2015 2014 2015 2014 U.S. Statutory rates 34 .0 % 34 .0 % 34.0 % 34.0 % Foreign income not recognized in the U.S. (34.0 ) (34.0 ) (34.0 ) (34.0 ) China income taxes 25.0 25.0 25.0 25.0 Change in valuation allowance (1) (25.0 ) (117.2 ) (25.0 ) (29.9 ) Non-deductible expenses-permanent difference (2) (5.8 ) (61.8 ) (27.9 ) (6.3 ) Effective tax rate (5.8 )% (154.0 )% 27.9 % (11.2 )% (1) It represents non-taxable expense reversal due to overall decrease in allowance for accounts receivables and advance to suppliers. (2) The 5.8% and (61.8)% rate adjustments for the three months ended September 30, 2015 and 2014, and the (27.9)% and (6.3)% rate adjustments for the six months ended September 30, 2015 and 2014 represents expenses primarily included stock option expense, legal, accounting and other expenses incurred by the Company that were not deductible for PRC income tax.
Schedule of taxes payable	September 30, March 31, VAT $ 380,254 $ 301,149 Income tax 7,556 8,007 Others 41,521 18,955 Total taxes payable $ 429,331 $ 328,111

Related Party Transactions an39

Related Party Transactions and Arrangements (Tables)	6 Months Ended
	Sep. 30, 2015
Related Party Transactions and Arrangements [Abstract]
Schedule of amounts payable to related parties	September 30, March 31, Due to cofounders (1): $ 576,818 $ 576,818 Due to a director and CEO (2): 2,182,756 2,152,922 Total $ 2,759,574 $ 2,729,740 (1) As of September 30, 2015 and March 31, 2015, amount due to cofounders represents contributions from the Owners to Jiuxin Management to enable Jiuxin Management to meet its approved PRC registered capital requirements. (2) Due to foreign exchange restrictions, the Company’s director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States.

Warrants Liabilities (Tables)

Warrants Liabilities (Tables)	6 Months Ended
	Sep. 30, 2015
Warrants Liabilities [Abstract]
Schedule of estimated fair value of warrants	Common Stock September 30, Stock price $ 1.82 Exercise price $ 1.20 Annual dividend yield 0 % Expected term (years) 0.99 Risk-free interest rate 0.33 % Expected volatility 105.77 %

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Sep. 30, 2015
Stockholders' Equity [Abstract]
Schedule of fair value of warrants	Terms of warrants 5 years Expected volatility 105.05 % Risk-free interest rate 1.72 % Expected dividend yield - %
Summary of stock warrant activities	Nine months ended September 30, 2015 Nine months ended September 30, 2014 Number Weight average exercise price Number Weight average exercise p rice Outstanding and exercisable at beginning of the period - $ - - $ - Issued during the period 672,000 3.10 - - Exercised during the period - - - - Cancelled or expired during the period - - - - Outstanding and exercisable at end of the period 672,000 $ 3.10 - $ - Range of exercise price - 3.10 - -

Income (Loss) Per Share (Tables

Income (Loss) Per Share (Tables)	6 Months Ended
	Sep. 30, 2015
Income (Loss) Per Share [Abstract]
Schedule of reconciliation of the basic and diluted earnings per share computation	Three months ended Six months ended 2015 2014 2015 2014 Net income (loss) attributable to controlling interest $ 151,175 $ (36,193 ) $ 261,786 $ (382,930 ) Weighted average shares used in basic computation 16,537,461 14,981,637 16,096,406 14,700,375 Diluted effect of purchase options and warrants 51,099 - 51,099 - Diluted effect of restricted shares - - - - Weighted average shares used in diluted computation 16,588,559 14,981,637 16,147,505 14,700,375 Income (loss) per share – Basic: Net income (loss) before noncontrolling interest $ 0.01 $ (0.00 ) $ 0.02 $ (0.03 ) Add: Net loss attributable to noncontrolling interest $ - $ - $ - $ - Net income (loss) attributable to controlling interest $ 0.01 $ (0.00 ) $ 0.02 $ (0.03 ) Loss per share – Diluted: Net income (loss) before noncontrolling interest $ 0.01 $ (0.00 ) $ 0.02 $ (0.03 ) Add: Net loss attributable to noncontrolling interest $ - $ - $ - $ - Net loss attributable to controlling interest $ 0.01 $ (0.00 ) $ 0.02 $ (0.03 )

Segments (Tables)

Segments (Tables)	6 Months Ended
	Sep. 30, 2015
Segments [Abstract]
Schedule of information by segment	Retail drugstores Online Pharmacy Drug wholesale Herb Total Revenue $ 13,103,135 $ 6,558,407 $ 2,916,084 $ - $ 22,577,626 Cost of goods 10,177,989 5,737,312 2,685,318 - 18,600,619 Gross profit $ 2,925,146 $ 821,095 $ 230,766 $ - $ 3,977,007 Selling expenses 3,230,986 51,462 136,307 - 3,418,755 General and administrative expenses 1,191,832 214,315 (47,827 )* (518,478 ) 839,842 (Loss) income from operations $ (1,497,672 ) $ 555,318 $ 142,286 $ 518,478 ) $ (281,590 ) Depreciation and amortization $ 134,720 $ - $ 130,103 $ 79,209 $ 344,032 Total capital expenditures $ 6,200 $ 690 $ (83 ) $ - $ 6,807 * include the accounts receivable and advance to suppliers allowance reversal of $850,079. Retail Online Drug Herb Total Revenue $ 12,406,038 $ 2,949,391 $ 3,088,636 $ - $ 18,444,065 Cost of goods 10,302,519 2,463,352 2,912,937 - 15,678,808 Gross profit $ 2,103,519 $ 486,039 $ 175,699 $ - $ 2,765,257 Selling expenses 1,795,108 666 138,006 - 1,933,780 General and administrative expenses 1,412,896 155,861 (911,544 )* 88,962 746,175 (Loss) income from operations $ (1,104,485 ) $ 329,512 $ 949,237 $ (88,962 ) $ 85,302 Depreciation and amortization $ 222,829 $ 1,376 $ 24,022 $ 80,081 $ 328,308 Total capital expenditures $ 107,573 $ 3,210 $ 6,106 $ - $ 116,889 * include the accounts receivable and advance to suppliers allowance reversal of $987,383. Retail Online pharmacy Drug Herb Total Revenue $ 25,274,023 $ 12,524,175 $ 6,090,720 $ - $ 43,888,918 Cost of goods 19,215,883 10,681,595 5,638,750 - 35,536,228 Gross profit $ 6,058,140 $ 1,842,580 $ 451,970 $ - $ 8,352,690 Selling expenses 5,805,454 458,712 250,958 - 6,515,124 General and administrative expenses 2,291,554 445,930 (467,225 ) (510,187 ) 1,760,072 (Loss) income from operations $ (2,038,868 ) $ 937,938 $ 668,237 $ 510,187 $ 77,494 Depreciation and amortization $ 329,727 $ - $ 273,609 $ 160,503 $ 763,839 Total capital expenditures $ 93,132 $ 6,669 $ 6,399 $ - $ 106,200 * include the accounts receivable and advance to suppliers allowance reversal of $1,586,818. Retail Online Drug Herb Total Revenue $ 23,001,797 $ 5,521,933 $ 6,379,567 $ - $ 34,903,297 Cost of goods 18,982,408 4,630,716 6,014,297 - 29,627,421 Gross profit $ 4,019,389 $ 891,217 $ 365,270 $ - $ 5,275,876 Selling expenses 3,465,497 666 236,194 3,702,357 General and administrative expenses 2,676,192 299,560 (1,323,439 ) 175,063 1,827,376 (Loss) income from operations $ (2,122,300 ) $ 590,991 $ 1,452,515 $ (175,063 ) $ (253,857 ) Depreciation and amortization $ 492,846 $ 3,538 $ 175,581 $ 160,605 $ 832,570 Total capital expenditures $ 141,800 $ 3,513 $ 76,258 $ - $ 221,571 * include the accounts receivable and advance to suppliers allowance reversal of $1,634,886.
Schedule of net revenue from external customers by main products	Three months ended Six months ended 2015 2014 2015 2014 Prescription drugs $ 4,789,007 $ 4,957,751 $ 9,435,383 $ 9,378,003 Over-the-counter drugs 5,436,301 4,291,738 10,332,993 8,234,531 Nutritional supplements 1,029,519 547,218 1,940,130 1,171,143 Traditional Chinese medicine 1,276,488 1,991,112 2,412,997 3,186,746 Sundry products 341,663 502,724 603,710 859,783 Medical devices 230,157 115,495 548,810 171,591 Total $ 13,103,135 $ 12,406,038 $ 25,274,023 $ 23,001,797 Three months ended Six months ended 2015 2014 2015 2014 Prescription drugs $ - $ - $ - $ - Over-the-counter drugs 1,730,043 826,755 3,610,327 1,519,598 Nutritional supplements 559,390 191,953 1,073,134 341,893 Traditional Chinese medicine - - - Sundry products 2,587,169 455,521 3,814,123 775,491 Medical devices 1,681,805 1,475,162 4,026,592 2,884,951 Total $ 6,558,407 $ 2,949,391 $ 12,524,175 $ 5,521,933 Three months ended Six months ended 2015 2014 2015 2014 Prescription drugs $ 1,808,043 $ 2,362,902 $ 3,711,364 $ 4,261,984 Over-the-counter drugs 1,077,992 611,219 2,274,770 1,948,429 Nutritional supplements 23,346 6,387 43,931 33,949 Traditional Chinese medicine - 80,905 - 89,268 Sundry products 3,482 6,583 6,414 6,777 Medical devices 3,221 20,640 54,240 39,160 Total $ 2,916,084 $ 3,088,636 $ 6,090,720 $ 6,379,567

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Sep. 30, 2015
Commitments and Contingencies [Abstract]
Schedule of company's commitments for minimum rental payments	Periods ending September 30, Retail Online Drug Herb farming Total 2015 $ 3,718,382 $ 200,848 $ 176,010 $ - $ 4,095,240 2016 2,843,385 218,175 150,171 - 3,211,731 2017 2,537,549 165,138 150,171 - 2,852,858 2018 2,034,545 138,619 150,171 - 2,323,335 2019 891,800 138,619 112,628 - 1,143,047 Thereafter 133,332 69,310 - - 202,642

Description of Business and O45

Description of Business and Organization (Details)	6 Months Ended
	Sep. 30, 2015
Variable Interest Entity [Line Items]
Variable Interest Entity, ownership percentage	100.00%
Renovation HK [Member]
Variable Interest Entity [Line Items]
Ownership background description	Incorporated in Hong Kong SAR on September 2, 2008
Variable Interest Entity, ownership percentage	100.00%
Jiuxin Management [Member]
Variable Interest Entity [Line Items]
Ownership background description	Established in the PRC on October 14, 2008 Deemed a wholly foreign owned enterprise (''WFOE'') under PRC law Registered capital of $4.5 million fully paid
Variable Interest Entity, ownership percentage	100.00%
Shouantang Technology [Member]
Variable Interest Entity [Line Items]
Ownership background description	Established in the PRC on October 14, 2008 Deemed a wholly foreign owned enterprise (''WFOE'') under PRC law Registered capital of $4.5 million fully paid
Variable Interest Entity, ownership percentage	100.00%
Qianhong Agriculture [Member]
Variable Interest Entity [Line Items]
Ownership background description	Established in the PRC on August 10, 2010 by Jiuxin Management Registered capital of RMB 10 million fully paid Carries out herb farming business
Variable Interest Entity, ownership percentage	100.00%
Quannuo Technology [Member]
Variable Interest Entity [Line Items]
Ownership background description	Established in the PRC on July 7, 2009 Registered capital of RMB 10 million fully paid Acquired by Shouantang Technology in November 2010 Operates the Company's online pharmacy website and provide software and technical support
Variable Interest Entity, ownership percentage	100.00%
Hangzhou Quannuo [Member]
Variable Interest Entity [Line Items]
Ownership background description	Established in the PRC on July 8, 2010 by Quannuo Technology Registered capital of RMB 800,000 fully paid Currently has no operation and has closed, pending dissolution
Variable Interest Entity, ownership percentage	100.00%
Jiuzhou Pharmacy [Member]
Variable Interest Entity [Line Items]
Ownership background description	Established in the PRC on September 9, 2003 Registered capital of RMB 5 million fully paid Operates the ''Jiuzhou Grand Pharmacy'' stores in Hangzhou	[1]
Variable Interest Entity, ownership description	VIE by contractual arrangements	[1],[2]
Jiuzhou Clinic [Member]
Variable Interest Entity [Line Items]
Ownership background description	Established in the PRC as a general partnership on October 10, 2003 Operates a medical clinic adjacent to one of Jiuzhou Pharmacy's stores	[1]
Variable Interest Entity, ownership description	VIE by contractual arrangements	[1],[2]
Jiuzhou Service [Member]
Variable Interest Entity [Line Items]
Ownership background description	Established in the PRC on November 2, 2005 Registered capital of RMB 500,000 fully paid Operates a medical clinic adjacent to one of Jiuzhou Pharmacy's stores	[1]
Variable Interest Entity, ownership description	VIE by contractual arrangements	[1],[2]
Jiuxin Medicine [Member]
Variable Interest Entity [Line Items]
Ownership background description	Established in PRC on December 31, 2003 Acquired by Jiuzhou Pharmacy in August 2011 Registered capital of RMB 10 million fully paid Carries out pharmaceutical distribution services
Variable Interest Entity, ownership description	VIE by contractual arrangements as a wholly-owned subsidiary of Jiuzhou Pharmacy	[2]
Jiutong Medical [Member]
Variable Interest Entity [Line Items]
Ownership background description	Established in the PRC on December 20, 2011 by Renovation Registered capital of $2.6 million fully paid Currently has no operation
Variable Interest Entity, ownership percentage	100.00%
Shouantang Bio [Member]
Variable Interest Entity [Line Items]
Ownership background description	Established in the PRC in October, 2014 by Shouantang Technology 100% held by Shouantang Technology Registered capital of RMB 1,000,000 fully paid Sells nutritional supplements under its own brand name
Variable Interest Entity, ownership description	VIE by contractual arrangements as a controlled entity of Jiuzhou Service	[2]
Jianshun [Member]
Variable Interest Entity [Line Items]
Ownership background description	Established in the PRC in May, 2015 35% held by Jiuzhou Pharmacy Manages sales on official website of the online pharmacy
Variable Interest Entity, ownership description	VIE by contractual arrangements as a controlled entity of Jiuzhou Pharmacy	[2]
Jiuyi Technology [Member]
Variable Interest Entity [Line Items]
Ownership background description	Established in the PRC on September 10, 2015 100% held by Renovation HK Technical support to online pharmacy
Variable Interest Entity, ownership percentage	100.00%
[1]	Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service have been under the common control of the three shareholders of Renovation (the "Owners") since their respective establishment dates, pursuant to agreements among the Owners to vote their interests in concert as memorialized in a voting agreement. Based on such voting agreement, the Company has determined that common control exists among these three companies. Operationally, the Owners have operated these three companies in conjunction with one another since each company's respective establishment date. Jiuxin Medicine is also deemed under the common control of the Owners as a subsidiary of Jiuzhou Pharmacy, as is Shouantang Health as a subsidiary of Jiuzhou Service and Jianshun as a subsidiary of Jiuzhou Pharmacy.
[2]	To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. As a result of these agreements, which obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for all three companies (as well as one subsidiary of Jiuzhou Pharmacy) as a variable interest entity ("VIE") under the accounting standards of the Financial Accounting Standards Board ("FASB"). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiary under the control of Jiuzhou Pharmacy (Shouantang Health), are consolidated into the financial statements of the Company.

Description of Business and O46

Description of Business and Organization (Detail Textual)		1 Months Ended	6 Months Ended
		Sep. 17, 2009shares	Sep. 30, 2015USD ($)	Sep. 30, 2015CNY (¥)	Mar. 31, 2015USD ($)	Mar. 31, 2015CNY (¥)	Mar. 31, 2014Clinic	Dec. 18, 2013	Jul. 31, 2012CNY (¥)	Jul. 16, 2010USD ($)
Business and Organization [Textual]
Entity Incorporation, Date of Incorporation			Dec. 19, 2006
Number of medical clinics owned | Clinic							5
Renovation HK [Member]
Business and Organization [Textual]
Issuance of equity consideration (in shares) | shares		7,900,000
Registered capital paid | $					$ 4,500,000
Jiuxin Management [Member]
Business and Organization [Textual]
Registered capital paid | $			$ 4,500,000
Shouantang Technology [Member]
Business and Organization [Textual]
Registered capital paid			20,000,000						¥ 11,000,000	$ 20,000,000
Qianhong Agriculture [Member]
Business and Organization [Textual]
Registered capital paid				¥ 10,000,000
Quannuo Technology [Member]
Business and Organization [Textual]
Registered capital paid				10,000,000
Hangzhou Quannuo [Member]
Business and Organization [Textual]
Registered capital paid				800,000
Jiuzhou Pharmacy [Member]
Business and Organization [Textual]
Registered capital paid	[1]			5,000,000
Jiuzhou Service [Member]
Business and Organization [Textual]
Percentage of ownership held								51.00%
Registered capital paid	[1]			500,000
Jiuxin Medicine [Member]
Business and Organization [Textual]
Registered capital paid				¥ 10,000,000
Jiutong Medical [Member]
Business and Organization [Textual]
Registered capital paid			$ 2,600,000			¥ 2,600,000
Shouantang Bio [Member]
Business and Organization [Textual]
Percentage of capital stock in exchange transaction			100.00%	100.00%
Registered capital paid				¥ 1,000,000
Jianshun [Member]
Business and Organization [Textual]
Percentage of capital stock in exchange transaction			35.00%	35.00%
Jiuyi Technology [Member]
Business and Organization [Textual]
Percentage of capital stock in exchange transaction			100.00%	100.00%
[1]	To comply with certain foreign ownership restrictions of pharmacy and medical clinic operators, Jiuxin Management entered into a series of contractual arrangements with Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service on August 1, 2009. These contractual arrangements are comprised of five agreements: consulting services agreement, operating agreement, equity pledge agreement, voting rights agreement and option agreement. As a result of these agreements, which obligate Jiuxin Management to absorb all of the risks of loss from the activities of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, and enable the Company (through Jiuxin Management) to receive all of their expected residual returns, the Company accounts for all three companies (as well as one subsidiary of Jiuzhou Pharmacy) as a variable interest entity ("VIE") under the accounting standards of the Financial Accounting Standards Board ("FASB"). Accordingly, the financial statements of Jiuzhou Pharmacy, Jiuzhou Clinic and Jiuzhou Service, as well as the subsidiary under the control of Jiuzhou Pharmacy (Shouantang Health), are consolidated into the financial statements of the Company.

Summary of Significant Accoun47

Summary of Significant Accounting Policies (Details)	6 Months Ended
	Sep. 30, 2015
Leasehold improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	10 years
Leasehold improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	3 years
Motor vehicles [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	5 years
Motor vehicles [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	3 years
Office equipment & furniture [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	5 years
Office equipment & furniture [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	3 years
Buildings [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives of property and equipment	35 years

Summary of Significant Accoun48

Summary of Significant Accounting Policies (Details 1)	6 Months Ended
	Sep. 30, 2015
Land use right [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets	50 years
Software [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated useful life of intangible assets	3 years

Summary of Significant Accoun49

Summary of Significant Accounting Policies (Details Textual)	3 Months Ended		6 Months Ended
	Sep. 30, 2015USD ($)Venders	Sep. 30, 2014USD ($)Vendor	Sep. 30, 2015USD ($)Vendor	Sep. 30, 2014USD ($)Vendor	Sep. 30, 2015CNY (¥)	Mar. 31, 2015USD ($)	Mar. 31, 2015CNY (¥)
Accounting Policies [Textual]
Benchmark percentage of the voting ownership interest for control and common control			50.00%
Ownership percentage			100.00%
Value added tax, percentage			17.00%
Term of agreement for operating leases			30 years
Advertising and promotion costs	$ 134,887	$ 81,321	$ 198,053	$ 131,239
Deposits not covered by insurance	$ 500,000		$ 500,000		¥ 16,404,370	$ 500,000	¥ 12,563,579
Foreign currency translation description			The balance sheet amounts, with the exception of equity, at September 30, 2015 and March 31, 2015 were translated at 1 RMB to $0.1572 USD and at 1 RMB to $0.1634 USD, respectively. The average translation rates applied to income and cash flow statement amounts for the six months ended September 30, 2015 and 2014 were at 1 RMB to $0.1617 USD and at 1 RMB to $0.1623 USD, respectively.
Total Purchases [Member] | Supplier Concentration Risk [Member]
Accounting Policies [Textual]
Concentration risk, percentage	24.50%	24.50%	25.30%	25.30%
Number of vendors	2	2	2	2
Total Sales [Member] | Customer Concentration Risk [Member]
Accounting Policies [Textual]
Concentration risk, percentage	18.20%	18.20%	18.20%	18.20%
Concentration risk, customer	No customer accounted for more than 10% of the Company's total sales or accounts receivable.	No customer accounted for more than 10% of the Company's total sales or accounts receivable.	No customer accounted for more than 10% of the Company's total sales or accounts receivable.
Number of vendors	1	1	1	1
Total Accounts Receivable [Member] | Customer Concentration Risk [Member]
Accounting Policies [Textual]
Concentration risk, percentage	10.00%	10.00%	10.00%	10.00%
Concentration risk, customer	No customer accounted for more than 10% of the Company's total sales or accounts receivable.	No customer accounted for more than 10% of the Company's total sales or accounts receivable.	No customer accounted for more than 10% of the Company's total sales or accounts receivable.	No customer accounted for more than 10% of the Company's total sales or accounts receivable.
Retail Site [Member] | Minimum [Member]
Accounting Policies [Textual]
Term of agreement for operating leases			3 years
Retail Site [Member] | Maximum [Member]
Accounting Policies [Textual]
Term of agreement for operating leases			8 years
Wholesale Warehouse Lease [Member] | Minimum [Member]
Accounting Policies [Textual]
Term of agreement for operating leases			10 years
Wholesale Warehouse Lease [Member] | Maximum [Member]
Accounting Policies [Textual]
Term of agreement for operating leases			30 years

Trade Accounts Receivable (Deta

Trade Accounts Receivable (Details) - USD ($)	Sep. 30, 2015	Mar. 31, 2015
Trade Accounts Receivable [Abstract]
Accounts receivable	$ 10,618,786	$ 12,108,561
Less: allowance for doubtful accounts	(2,104,320)	(2,870,818)
Trade accounts receivable, net	$ 8,514,466	$ 9,237,743

Trade Accounts Receivable (De51

Trade Accounts Receivable (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Receivables [Textual]
Accounts receivable written off	$ 31,541	$ 64,636	$ 91,873	$ 129,494

Other Current Assets (Details)

Other Current Assets (Details) - USD ($)		Sep. 30, 2015	Mar. 31, 2015
Other Current Assets [Abstract]
Prepaid rental expenses	[1]	$ 1,058,852	$ 1,712,018
Prepaid and other current assets		470,273	488,820
Total		$ 1,529,125	$ 2,200,838
[1]	Represents store rental expenses that were usually prepaid and amortized over the prepayment period.

Property and Equipment (Details

Property and Equipment (Details) - USD ($)		Sep. 30, 2015	Mar. 31, 2015
Property, Plant and Equipment [Line Items]
Total		$ 22,341,643	$ 23,115,486
Less: Accumulated depreciation		(13,816,981)	(13,606,043)
Impairment	[1]	(2,359,599)	(2,452,662)
Property and equipment, net		6,165,063	7,056,781
Building [Member]
Property, Plant and Equipment [Line Items]
Total		1,685,509	1,751,986
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Total		12,375,652	12,792,714
Farmland development cost [Member]
Property, Plant and Equipment [Line Items]
Total		1,880,016	1,954,165
Office equipment and furniture [Member]
Property, Plant and Equipment [Line Items]
Total		5,757,427	5,949,193
Motor vehicles [Member]
Property, Plant and Equipment [Line Items]
Total		$ 643,038	$ 667,428
[1]	The variance of impairment from March 31, 2015 to September 30, 2015 is solely caused by exchange rate variance.

Property and Equipment (Detai54

Property and Equipment (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015
Property and Equipment [Textual]
Total depreciation expense for property and equipment	$ 336,225	$ 322,362	$ 748,018	$ 816,444
Impairment of fixed assets					$ 1,053,765

Advances to Suppliers (Details)

Advances to Suppliers (Details) - USD ($)	Sep. 30, 2015	Mar. 31, 2015
Advances to Suppliers [Abstract]
Advance to suppliers	$ 4,990,008	$ 5,942,866
Less: allowance for doubtful accounts	(249,447)	(1,225,514)
Advance to suppliers, net	$ 4,740,561	$ 4,717,352

Inventory (Details)

Inventory (Details) - USD ($)	Sep. 30, 2015	Mar. 31, 2015
Inventory [Abstract]
Finished goods	$ 11,393,972	$ 10,538,591

Farmland Assets (Details)

Farmland Assets (Details) - USD ($)		Sep. 30, 2015	Mar. 31, 2015
Farmland Assets [Abstract]
Farmland assets		$ 2,512,304	$ 2,530,558
Less: impairments	[1]	(794,850)	(826,199)
Farmland assets, net		$ 1,717,454	$ 1,704,359
[1]	The estimated fair value is estimated to be lower than its investment value in fiscal 2014 and 2015. The slight decrease in the impairment amount from March 31, 2015 to September 30, 2015 is caused by exchange rate variance.

Long Term Deposits, Landlords (

Long Term Deposits, Landlords (Details) - USD ($)	Sep. 30, 2015	Mar. 31, 2015
Long Term Deposits, Landlords [Abstract]
Long term deposits	$ 2,485,977	$ 2,584,025

Other Noncurrent Assets (Detail

Other Noncurrent Assets (Details)	Sep. 30, 2015USD ($)
Years ending September 30,
2,016	$ 66,775
2,017	66,775
2,018	66,775
2,019	66,775
2,020	66,775
Thereafter	$ 1,196,755

Other Noncurrent Assets (Deta60

Other Noncurrent Assets (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015
Schedule of Other Assets Noncurrent [Line Items]
Other noncurrent assets	$ 2,631,030		$ 2,631,030		$ 2,734,798
Term of agreement for operating land lease			30 years
Deposit included in prepayment	1,100,400		$ 1,100,400
Amortization of prepayment for lease of land use right	$ 17,438	$ 16,761	$ 33,387	$ 33,517

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)		Sep. 30, 2015	Mar. 31, 2015
Acquired Finite-Lived Intangible Assets [Line Items]
Total other intangible assets		$ 3,524,796	$ 3,664,602
Less: accumulated amortization		(518,150)	(522,599)
Intangible assets, net		3,006,646	3,142,003
Land use rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Total other intangible assets	[1]	1,532,944	1,593,403
Software [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Total other intangible assets		458,433	477,302
License [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Total other intangible assets	[2]	1,510,692	1,570,274
Goodwill [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Total other intangible assets	[2]	$ 22,727	$ 23,623
[1]	In July 2013, the Company purchased the land use right of a plot of farmland in Lin'An, Hangzhou, intended for the establishment of an herb processing plant in the future. However, as our farming business in Lin'An has not grown, the Company does not expect completion of the plant in near future.
[2]	As of September 30, 2015, the intangible assets with indefinite life consisted of the following, which were generated through the acquisition of Sanhao Pharmacy.

Intangible Assets (Details 1)

Intangible Assets (Details 1)	6 Months Ended
	Sep. 30, 2015USD ($)
Indefinite-lived Intangible Assets [Line Items]
Preliminary Fair value	$ 1,589,606
Currency translation adjustment	(56,187)
Net carrying value	1,533,419
Goodwill [Member]
Indefinite-lived Intangible Assets [Line Items]
Preliminary Fair value	23,560
Currency translation adjustment	(833)
Net carrying value	22,727
License [Member]
Indefinite-lived Intangible Assets [Line Items]
Preliminary Fair value	1,566,046	[1]
Currency translation adjustment	(55,354)	[1]
Net carrying value	$ 1,510,692	[1]
[1]	This represents the fair value of the licenses of insurance applicable drugstores acquired from Sanhao Pharmacy. The licenses allow patients to pay by the insurance card at stores and the stores can get reimbursed from the Human Resource and Social Security Department of Hangzhou City..

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Intangible Assets [Abstract]
Amortization expense of intangibles	$ 7,808	$ 7,864	$ 15,821	$ 15,883

Notes Payable (Details)

Notes Payable (Details) - USD ($)		6 Months Ended
		Sep. 30, 2015	Mar. 31, 2015
Short-term Debt [Line Items]
Notes payable		$ 16,923,068	$ 15,752,969
Jiuzhou Pharmacy [Member] | HUB [Member] | 08/05/14 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Aug. 4, 2015
Notes payable	[1]		1,634,000
Jiuzhou Pharmacy [Member] | HUB [Member] | 10/09/14 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Apr. 9, 2015
Notes payable	[1]		784,320
Jiuzhou Pharmacy [Member] | HUB [Member] | 10/09/14 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Apr. 9, 2015
Notes payable	[1]		1,187,918
Jiuzhou Pharmacy [Member] | HUB [Member] | 12/05/14 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Jun. 5, 2015
Notes payable	[1]		1,329,651
Jiuzhou Pharmacy [Member] | HUB [Member] | 12/26/14 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Jun. 26, 2015
Notes payable	[1]		1,601,320
Jiuzhou Pharmacy [Member] | HUB [Member] | 03/04/15 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Sep. 4, 2015
Notes payable	[1]		1,470,600
Jiuzhou Pharmacy [Member] | HUB [Member] | 03/13/14 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Sep. 13, 2015
Notes payable	[1]		$ 604,580
Jiuzhou Pharmacy [Member] | HUB [Member] | 04/08/15 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Oct. 8, 2015
Notes payable	[1]	$ 1,587,720
Jiuzhou Pharmacy [Member] | HUB [Member] | 05/15/15 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Nov. 15, 2015
Notes payable	[1]	$ 1,502,832
Jiuzhou Pharmacy [Member] | HUB [Member] | 06/29/15 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Dec. 29, 2015
Notes payable	[1]	$ 2,431,884
Jiuzhou Pharmacy [Member] | HUB [Member] | 04/22/15 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Apr. 21, 2016
Notes payable	[1]	$ 1,572,000
Jiuzhou Pharmacy [Member] | HUB [Member] | 04/29/15 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Apr. 28, 2016
Notes payable	[1]	$ 3,379,800
Jiuzhou Pharmacy [Member] | HUB [Member] | 08/05/15 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Feb. 5, 2016
Notes payable	[1]	$ 1,782,648
Jiuzhou Pharmacy [Member] | HUB [Member] | 09/06/15 [Member]
Short-term Debt [Line Items]
Maturity date	[1]	Mar. 5, 2016
Notes payable	[1]	$ 1,902,765
Jiuzhou Pharmacy [Member] | BOH [Member] | 11/06/14 [Member]
Short-term Debt [Line Items]
Maturity date	[2]	May 6, 2015
Notes payable	[2]		$ 2,908,520
Jiuzhou Pharmacy [Member] | BOH [Member] | 02/09/15 [Member]
Short-term Debt [Line Items]
Maturity date	[2]	Aug. 9, 2015
Notes payable	[2]		1,993,480
Jiuzhou Pharmacy [Member] | BOH [Member] | 06/04/15 [Member]
Short-term Debt [Line Items]
Maturity date	[2]	Dec. 4, 2015
Notes payable	[2]	$ 2,326,560
Jiuzhou Pharmacy [Member] | ICBC [Member] | 12/26/14 [Member]
Short-term Debt [Line Items]
Maturity date	[3]	Jun. 25, 2015
Notes payable	[3]		$ 2,238,580
Jiuzhou Pharmacy [Member] | ICBC [Member] | 04/10/15 [Member]
Short-term Debt [Line Items]
Maturity date	[3]	Oct. 9, 2015
Notes payable	[3]	$ 436,859
[1]	As of March 31, 2015, the Company had $8,612,389 (RMB52,707,400) of notes payable from HUB. The Company is required to hold restricted cash of $4,763,309 (RMB 29,151,220) with HUB as collateral against these bank notes. As of September 30, 2015, the Company had $14,159,649 (RMB 90,074,100) of notes payable from HUB. The Company is required to hold restricted cash of $10,452,421 (RMB66,491,230) with HUB as collateral against these bank notes.
[2]	As of March 31, 2015, the Company had $4,902,000 (RMB30,000,000) of notes payable from BOH. The land use right of the farmland in Lin'An, Hangzhou is pledged as collateral for these bank acceptance notes (see Note 12). The Company is required to hold restricted cash of $2,287,600 (RMB 14,000,000) with BOH as collateral against these bank notes. As of September 30, 2015, the Company had $2,326,560 (RMB 14,800,000) of notes payable from BOH. The land use right of the farmland in Lin'An, Hangzhou is pledged as collateral for these bank acceptance notes (see Note 12). The Company is required to hold restricted cash of $1,068,960 (RMB 6,800,000) with BOH as collateral against these bank notes.
[3]	As of March 31, 2015, the Company had $2,238,580 (RMB 13,700,000) of notes payable from ICBC, with restricted cash of $671,574 (RMB 4,110,000) held at the bank. As of September 30, 2015, the Company had $436,859 (RMB 2,779,000) of notes payable from ICBC, with restricted cash of $131,058 (RMB833,700) held at the bank.

Notes Payable (Details Textual)

Notes Payable (Details Textual)	Sep. 30, 2015USD ($)	Sep. 30, 2015CNY (¥)	Mar. 31, 2015USD ($)	Mar. 31, 2015CNY (¥)
Debt Instrument [Line Items]
Notes Payable	$ 16,923,068		$ 15,752,969
Level 2 [Member]
Debt Instrument [Line Items]
Notes Payable	16,630,964		15,743,000
Line of Credit [Member]
Debt Instrument [Line Items]
Notes Payable	16,920,000
Restricted cash	12,760,000
Line of Credit [Member] | ICBC [Member]
Debt Instrument [Line Items]
Aggregate maximum line of credit amount	9,130,000
Line of Credit [Member] | HUB [Member]
Debt Instrument [Line Items]
Aggregate maximum line of credit amount	9,000
Line of Credit [Member] | BOH [Member]
Debt Instrument [Line Items]
Aggregate maximum line of credit amount	9,130,000
Notes Payable [Member] | ICBC [Member]
Debt Instrument [Line Items]
Notes Payable	436,859	¥ 2,779,000	2,238,580	¥ 13,700,000
Restricted cash	131,058	833,700	671,574	4,110,000
Notes Payable [Member] | HUB [Member]
Debt Instrument [Line Items]
Notes Payable	14,159,649	90,074,100	8,612,389	52,707,400
Restricted cash	10,452,421	66,491,230	4,763,309	29,151,220
Notes Payable [Member] | BOH [Member]
Debt Instrument [Line Items]
Notes Payable	2,326,560	14,800,000	4,902,000	30,000,000
Restricted cash	1,068,960	¥ 6,800,000	$ 2,287,600	¥ 14,000,000
Notes Payable [Member] | Line of Credit [Member]
Debt Instrument [Line Items]
Bank facilities available for future borrowing	$ 1,510,000

Taxes (Details)

Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Taxes [Abstract]
Income tax	$ (38,062)	$ 22,680	$ 44,125	$ 38,821

Taxes (Details 1)

Taxes (Details 1)	6 Months Ended
	Sep. 30, 2015
Jo-Jo Drugstores [Member]
Income Taxes [Line Items]
Income Tax Jurisdiction	United States
Renovation [Member]
Income Taxes [Line Items]
Income Tax Jurisdiction	Hong Kong, PRC
All other entities [Member]
Income Taxes [Line Items]
Income Tax Jurisdiction	Mainland, PRC

Taxes (Details 2)

Taxes (Details 2)		3 Months Ended		6 Months Ended
		Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Taxes [Abstract]
U.S. Statutory rates		34.00%	34.00%	34.00%	34.00%
Foreign income not recognized in the U.S.		(34.00%)	(34.00%)	(34.00%)	(34.00%)
China income taxes		25.00%	25.00%	25.00%	25.00%
Change in valuation allowance	[1]	(25.00%)	(117.20%)	(25.00%)	(29.90%)
Non-deductible expenses-permanent difference	[2]	(5.80%)	(61.80%)	(27.90%)	(6.30%)
Effective tax rate		(5.80%)	(154.00%)	27.90%	(11.20%)
[1]	It represents non-taxable expense reversal due to overall decrease in allowance for accounts receivables and advance to suppliers.
[2]	The 5.8% and (61.8)% rate adjustments for the three months ended September 30, 2015 and 2014, and the (27.9)% and (6.3)% rate adjustments for the six months ended September 30, 2015 and 2014 represents expenses primarily included stock option expense, legal, accounting and other expenses incurred by the Company that were not deductible for PRC income tax.

Taxes (Details 3)

Taxes (Details 3) - USD ($)	Sep. 30, 2015	Mar. 31, 2015
Taxes [Abstract]
VAT	$ 380,254	$ 301,149
Income tax	7,556	8,007
Others	41,521	18,955
Total taxes payable	$ 429,331	$ 328,111

Taxes (Details Textual)

Taxes (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Taxes [Abstract]
Estimated net operating loss carryforwards for U.S. income tax purposes	$ 1,503,000		$ 1,503,000
Expiration date			Dec. 31, 2032
Valuation allowance, percentage			100.00%
Effective income tax rate adjustments	5.80%	(61.80%)	(27.90%)	(6.30%)

Postretirement Benefits (Detail

Postretirement Benefits (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Postretirement Benefits [Abstract]
Employment benefits and pension contribution	$ 245,394	$ 209,773	$ 468,405	$ 400,271

Related Party Transactions an72

Related Party Transactions and Arrangements (Details) - USD ($)		Sep. 30, 2015	Mar. 31, 2015
Related Party Transaction [Line Items]
Amounts payable to related parties, Total		$ 2,759,574	$ 2,729,740
Due to cofounders [Member]
Related Party Transaction [Line Items]
Amounts payable to related parties, Total	[1]	576,818	576,818
Due to a director and CEO [Member]
Related Party Transaction [Line Items]
Amounts payable to related parties, Total	[2]	$ 2,182,756	$ 2,152,922
[1]	As of September 30, 2015 and March 31, 2015, amount due to cofounders represents contributions from the Owners to Jiuxin Management to enable Jiuxin Management to meet its approved PRC registered capital requirements.
[2]	Due to foreign exchange restrictions, the Company's director and CEO, Mr. Lei Liu personally lent U.S. dollars to the Company to facilitate its payments of expenses in the United States.

Related Party Transactions an73

Related Party Transactions and Arrangements (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015
Related Party Transaction [Line Items]
Notes payable, related parties	$ 7,425,201		$ 7,425,201		$ 5,790,471
Mr. Lei Liu [Member]
Related Party Transaction [Line Items]
Lease expiration date			Sep. 30, 2015
Rent expense	$ 23,940	$ 24,350	$ 48,510	$ 48,692

Warrants Liabilities (Details)

Warrants Liabilities (Details) - Common Stock Warrants [Member]	6 Months Ended
	Sep. 30, 2015$ / shares	[1]
Class of Warrant or Right [Line Items]
Stock price	$ 1.82
Exercise price	$ 1.20
Annual dividend yield	0.00%
Expected term (years)	11 months 27 days
Risk-free interest rate	0.33%
Expected volatility	105.77%
[1]	As of September 30, 2015, the warrant had not been exercised.

Warrants Liabilities (Details T

Warrants Liabilities (Details Textual) - Warrants [Member] - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Sep. 26, 2013	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Warrants (Textual)
Fair value estimation method				Black-Scholes Model
Fair value of warrant liability	$ 33,606
Recognized gain (loss) in fair value of warrant liability		$ 200,903	$ 58,318	$ 158,064	$ 27,994
Consulting firm [Member]
Warrants (Textual)
Stock purchase price per share (in dollars per share)	$ 1.20
Stock Issued During Period, Shares, Issued for Services	150,000
Warrants exercisable date	Sep. 25, 2016

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Warrant [Member]	6 Months Ended
	Sep. 30, 2015
Terms of warrants	5 years
Expected volatility	105.05%
Risk-free interest rate	1.72%
Expected dividend yield

Stockholders' Equity (Details 1

Stockholders' Equity (Details 1) - Warrants [Member] - $ / shares	6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Warrants, Outstanding and exercisable at beginning of the period
Issued during the period	672,000
Exercised during the period
Cancelled or expired during the period
Warrants, Outstanding and exercisable at end of the period	672,000
Weighted Average Exercise Price, Beginning balance
Weight average exercise price, Issued during the period	$ 3.10
Weighted Average Exercise Price, Ending balance	3.10
Range of exercise price	$ 3.10

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	Jul. 24, 2015	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Stockholders' Equity (Textual)
Share based compensation expense		$ 124,033		$ 248,066
Statutory accounts percentage		34.00%	34.00%	34.00%	34.00%
Reserve fund percentage				50.00%
Sale of stock offering percentage				6.00%
Issuance of stock purchase options to an investor				$ 1,231,067
Issuance of stock purchase options to an investment bank				147,728
Warrant [Member]
Stockholders' Equity (Textual)
Purchase of warrants investors	600,000
Purchase of warrants underwriter	72,000
Exercise price of warrants	$ 3.10
Maturity date	Jan. 18, 2021
Weighted average fair value of warrants granted					$ 1.20
Aggregated intrinsic value of warrants outstanding and exercisable		$ 807,081		$ 807,081

Income (Loss) Per Share (Detail

Income (Loss) Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income (Loss) Per Share [Abstract]
Net income (loss) attributable to controlling interest	$ 151,175	$ (36,193)	$ 261,786	$ (382,930)
Weighted average shares used in basic computation	16,537,461	14,981,637	16,096,406	14,700,375
Diluted effect of purchase options and warrants	51,099		51,099
Diluted effect of restricted shares
Weighted average shares used in diluted computation	16,588,559	14,981,637	16,147,505	14,700,375
Income (loss) per share - Basic:
Net income (loss) before noncontrolling interest	$ 0.01	$ 0	$ 0.02	$ (0.03)
Add: Net loss attributable to noncontrolling interest
Net income (loss) attributable to controlling interest	$ 0.01	$ 0	$ 0.02	$ (0.03)
Loss per share - Diluted:
Net income (loss) before noncontrolling interest	$ 0.01	$ 0	$ 0.02	$ (0.03)
Add: Net loss attributable to noncontrolling interest
Net loss attributable to controlling interest	$ 0.01	$ 0	$ 0.02	$ (0.03)

Income (Loss) Per Share (Deta80

Income (Loss) Per Share (Details Textual) - Options and Warrant [Member] - shares	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from calculation of diluted earnings per share	967,000	600,000	967,000	600,000
Investor [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from calculation of diluted earnings per share			72,000

Segments (Details)

Segments (Details) - USD ($)	3 Months Ended				6 Months Ended
	Sep. 30, 2015		Sep. 30, 2014		Sep. 30, 2015		Sep. 30, 2014
Segment Reporting Information [Line Items]
Revenue	$ 22,577,626		$ 18,444,065		$ 43,888,918		$ 34,903,297
Cost of goods	18,600,619		15,678,808		35,536,228		29,627,421
Gross profit	3,977,007		2,765,257		8,352,690		5,275,876
Selling expenses	3,418,755		1,933,780		6,515,124		3,702,357
General and administrative expenses	839,842		746,175		1,760,072		1,827,376
(Loss) income from operations	(281,590)		85,302		77,494		(253,857)
Depreciation and amortization	344,032		328,308		763,839		832,570
Total capital expenditures	6,807		116,889		106,200		221,571
Retail drugstores [Member]
Segment Reporting Information [Line Items]
Revenue	13,103,135		12,406,038		25,274,023		23,001,797
Cost of goods	10,177,989		10,302,519		19,215,883		18,982,408
Gross profit	2,925,146		2,103,519		6,058,140		4,019,389
Selling expenses	3,230,986		1,795,108		5,805,454		3,465,497
General and administrative expenses	1,191,832		1,412,896		2,291,554		2,676,192
(Loss) income from operations	(1,497,672)		(1,104,485)		(2,038,868)		(2,122,300)
Depreciation and amortization	134,720		222,829		329,727		492,846
Total capital expenditures	6,200		107,573		93,132		141,800
Online Pharmacy [Member]
Segment Reporting Information [Line Items]
Revenue	6,558,407		2,949,391		12,524,175		5,521,933
Cost of goods	5,737,312		2,463,352		10,681,595		4,630,716
Gross profit	821,095		486,039		1,842,580		891,217
Selling expenses	51,462		666		458,712		666
General and administrative expenses	214,315		155,861		445,930		299,560
(Loss) income from operations	$ 555,318		329,512		$ 937,938		590,991
Depreciation and amortization			1,376				3,538
Total capital expenditures	$ 690		3,210		$ 6,669		3,513
Drug Wholesale [Member]
Segment Reporting Information [Line Items]
Revenue	2,916,084		3,088,636		6,090,720		6,379,567
Cost of goods	2,685,318		2,912,937		5,638,750		6,014,297
Gross profit	230,766		175,699		451,970		365,270
Selling expenses	136,307		138,006		250,958		236,194
General and administrative expenses	(47,827)	[1]	(911,544)	[2]	(467,225)	[3]	(1,323,439)	[4]
(Loss) income from operations	142,286		949,237		668,237		1,452,515
Depreciation and amortization	130,103		24,022		273,609		175,581
Total capital expenditures	$ (83)		$ 6,106		$ 6,399		$ 76,258
Herbs farming [Member]
Segment Reporting Information [Line Items]
Revenue
Cost of goods
Gross profit
Selling expenses
General and administrative expenses	$ (518,478)		$ 88,962		$ (510,187)		$ 175,063
(Loss) income from operations	(518,478)		(88,962)		510,187		(175,063)
Depreciation and amortization	$ 79,209		$ 80,081		$ 160,503		$ 160,605
Total capital expenditures
[1]	include the accounts receivable and advance to suppliers allowance reversal of $850,079.
[2]	include the accounts receivable and advance to suppliers allowance reversal of $987,383.
[3]	include the accounts receivable and advance to suppliers allowance reversal of $1,586,818.
[4]	include the accounts receivable and advance to suppliers allowance reversal of $1,634,886.

Segments (Details 1)

Segments (Details 1) - Operating Segments [Member] - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Retail drugstores [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	$ 13,103,135	$ 12,406,038	$ 25,274,023	$ 23,001,797
Retail drugstores [Member] | Prescription drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	4,789,007	4,957,751	9,435,383	9,378,003
Retail drugstores [Member] | Over-the-counter drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	5,436,301	4,291,738	10,332,993	8,234,531
Retail drugstores [Member] | Nutritional supplements [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	1,029,519	547,218	1,940,130	1,171,143
Retail drugstores [Member] | Traditional Chinese medicine [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	1,276,488	1,991,112	2,412,997	3,186,746
Retail drugstores [Member] | Sundry products [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	341,663	502,724	603,710	859,783
Retail drugstores [Member] | Medical devices [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	230,157	115,495	548,810	171,591
Online Pharmacy [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	$ 6,558,407	$ 2,949,391	$ 12,524,175	$ 5,521,933
Online Pharmacy [Member] | Prescription drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers
Online Pharmacy [Member] | Over-the-counter drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	$ 1,730,043	$ 826,755	$ 3,610,327	$ 1,519,598
Online Pharmacy [Member] | Nutritional supplements [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	$ 559,390	$ 191,953	$ 1,073,134	$ 341,893
Online Pharmacy [Member] | Traditional Chinese medicine [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers
Online Pharmacy [Member] | Sundry products [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	$ 2,587,169	$ 455,521	$ 3,814,123	$ 775,491
Online Pharmacy [Member] | Medical devices [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	1,681,805	1,475,162	4,026,592	2,884,951
Drug Wholesale [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	2,916,084	3,088,636	6,090,720	6,379,567
Drug Wholesale [Member] | Prescription drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	1,808,043	2,362,902	3,711,364	4,261,984
Drug Wholesale [Member] | Over-the-counter drugs [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	1,077,992	611,219	2,274,770	1,948,429
Drug Wholesale [Member] | Nutritional supplements [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	$ 23,346	6,387	$ 43,931	33,949
Drug Wholesale [Member] | Traditional Chinese medicine [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers		80,905		89,268
Drug Wholesale [Member] | Sundry products [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	$ 3,482	6,583	$ 6,414	6,777
Drug Wholesale [Member] | Medical devices [Member]
Revenue from External Customer [Line Items]
Net revenue from external customers	$ 3,221	$ 20,640	$ 54,240	$ 39,160

Segments (Details Textual)

Segments (Details Textual)	3 Months Ended		6 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)Segment	Sep. 30, 2014USD ($)
Revenue From External Customer [Line Items]
Number of operating segments | Segment			4
Operating Segments [Member]
Revenue From External Customer [Line Items]
Accounts receivable and advance to supplier allowance reversal	$ 850,079	$ 987,383	$ 1,586,818	$ 1,634,886

Commitments and Contingencies84

Commitments and Contingencies (Details)	Sep. 30, 2015USD ($)
Commitments and Contingencies [Line Items]
2,015	$ 4,095,240
2,016	3,211,731
2,017	2,852,858
2,018	2,323,335
2,019	1,143,047
Thereafter	202,642
Retail drugstores [Member]
Commitments and Contingencies [Line Items]
2,015	3,718,382
2,016	2,843,385
2,017	2,537,549
2,018	2,034,545
2,019	891,800
Thereafter	133,332
Online Pharmacy [Member]
Commitments and Contingencies [Line Items]
2,015	200,848
2,016	218,175
2,017	165,138
2,018	138,619
2,019	138,619
Thereafter	69,310
Drug Wholesale [Member]
Commitments and Contingencies [Line Items]
2,015	176,010
2,016	150,171
2,017	150,171
2,018	150,171
2,019	$ 112,628
Thereafter
Herbs farming [Member]
Commitments and Contingencies [Line Items]
2,015
2,016
2,017
2,018
2,019
Thereafter

Commitments and Contingencies85

Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Commitments and contingencies (Textual)
Total rent expense	$ 1,178,159	$ 1,215,232	$ 2,427,544	$ 2,397,776

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	1 Months Ended	6 Months Ended
	Oct. 31, 2015	Sep. 30, 2015	Sep. 30, 2014
Subsequent Events (Textual)
Repayments of bank debt		$ 31,665	$ 162,330
Subsequent Event [Member] | HUB [Member]
Subsequent Events (Textual)
Repayments of bank debt	$ 1,587,720
Subsequent Event [Member] | Industrial And Commercial Bank Of China [Member]
Subsequent Events (Textual)
Repayments of bank debt	$ 436,859